Bone Giant Cell Tumor

MONDO:0005674 Pathograph 24 Show in embeddings browser

Giant cell tumor of bone (GCTB, historically "osteoclastoma") is a locally aggressive, rarely metastasizing primary bone neoplasm that arises in the epiphyseal-metaphyseal region of long bones in skeletally mature young adults. It is defined by a somatic H3-3A (H3F3A) p.Gly34Trp oncohistone mutation confined to a neoplastic mesenchymal stromal cell population, which is arrested in osteoblastic differentiation and drives paracrine recruitment of a large, non-neoplastic osteoclast compartment. The multinucleated osteoclast-like giant cells that give the tumor its name are therefore reactive rather than neoplastic, and their RANKL-driven resorptive activity produces the defining geographic osteolysis. The disease is the clearest human example of a neoplasm whose destructive phenotype is executed almost entirely by a recruited bystander cell type - the mechanistic basis for treating it with the anti-RANKL antibody denosumab, and for the tumor's regrowth when that drug is withdrawn while the mutant stroma persists.

Ask OpenScientist

Ask a research question about Bone Giant Cell Tumor. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part

Discussions and Knowledge Gaps

Does the H3.3-G34W oncohistone initiate a giant cell tumor in vivo, and does the stromal-to-osteoclast paracrine loop operate as modeled when both compartments are present in a living skeleton?

KNOWLEDGE GAP OPEN gctb_no_in_vivo_g34w_model

Attached to

pathophysiology#Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells pathophysiology#Enhancer-Level SCUBE3 Repression

Every mechanistic step curated in this entry between the mutation and the osteoclast compartment - the epigenetic reprogramming, the differentiation block, SCUBE3 de-repression, the SEMA4D return signal - rests on patient-derived cultures, edited tumor-derived cell lines, and monocyte co-cultures. No genetically engineered animal carrying a knock-in G34W allele was identified in this curation pass. That matters more here than in most diseases, because the central claim is specifically about cross-talk between two cell compartments: a monoculture cannot test it, and a co-culture reconstitutes it only in the absence of bone matrix, vasculature, and an intact recruitment step. The tumor-formation experiment that establishes necessity was performed in cells that were already tumor-derived, so initiation from a normal mesenchymal progenitor remains untested.

Proposed experiments

Conditional H3-3A G34W knock-in in the osteoblast lineage

gctb_conditional_g34w_knockin

Generate a conditional knock-in of the G34W allele driven in mesenchymal or osteoprogenitor lineages and determine whether a giant-cell-rich osteolytic lesion arises, whether the recruited osteoclasts are genotypically wild type, and whether Scube3 is repressed in the mutant stroma in situ.

Readouts

Formation of a giant-cell-rich osteolytic lesion

Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells

Direction: INCREASED

Interpretation: Lesion formation from a normal progenitor would establish sufficiency, which the existing edited-cell experiment cannot.

Show evidence (1 reference)

PMID:32967858 SUPPORT In Vitro

"Here, we show H3.3 G34W is necessary for tumor formation."

The existing necessity result this proposed readout would extend to sufficiency in vivo.

Scube3 expression in mutant stroma in situ

Enhancer-Level SCUBE3 Repression

Direction: DECREASED

Interpretation: In vivo confirmation that the de-repression step operates outside culture.

Show evidence (1 reference)

PMID:36138226 SUPPORT In Vitro

"Transcriptional changes in SCUBE3 are associated with altered histone marks and H3.3G34W enrichment at its enhancer regions."

The in vitro finding this readout is designed to test in a living skeleton.

Show evidence (1 reference)

PMID:36138226 SUPPORT In Vitro

"While these striking features imply a pathogenic interaction between mesenchymal and myelomonocytic lineages during GCT development, the underlying mechanisms remain unknown."

States the two-compartment interaction that only an in vivo model can test intact, motivating this experiment.

Show evidence (1 reference)

PMID:32967858 SUPPORT In Vitro

"By profiling the epigenome, transcriptome, and secreted proteome of patient samples and tumor-derived cells CRISPR-Cas9-edited for H3.3 G34W"

Documents that the necessity evidence comes from edited tumor-derived cells, the limitation this gap identifies.

Is the only naturally occurring animal counterpart of this disease driven by the same oncohistone, or does the canine tumor reach the same histology by a different molecular route?

HUMAN MODEL MISMATCH OPEN gctb_canine_driver_mismatch

Attached to

pathophysiology#Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells

The canine vertebral case reproduces the human tumor's architecture - osteoclastic giant cells evenly distributed among spindled mononuclear cells - and its destructive osteolysis, yet showed no nuclear reactivity with the H3.3 G34W mutation-specific antibody. Three readings are compatible with that result and they have different consequences. If the antibody, validated only in human tissue, simply fails to cross-react, the dog is a usable model of the human mechanism. If canine H3.3 differs in sequence context around codon 34, the species is uninformative about this driver. If canine giant cell tumors are genuinely driven by something else, then the shared histology is convergent, and the tumor's architecture is a general outcome of stromal-osteoclast cross-talk rather than a specific consequence of this oncohistone - which would be the most interesting result of the three, and would argue that the histology is not diagnostic of the mechanism. Nothing short of sequencing distinguishes them.

Proposed experiments

Targeted sequencing of H3-3A codon 34 in canine giant cell tumors

gctb_canine_h3f3a_sequencing

Sequence the H3-3A codon 34 region in a series of canine giant cell bone tumors, alongside alignment of the canine H3.3 epitope against the human sequence the antibody was raised to, to separate assay failure from true molecular divergence.

Readouts

Presence of a codon 34 substitution in canine tumor stromal cells

Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells

Direction: UNCHANGED

Interpretation: Absence of any codon 34 change with a conserved epitope would establish genuine divergence; presence with a negative stain would establish assay failure. Direction is recorded as UNCHANGED because the informative result is the wild-type one.

Show evidence (1 reference)

PMID:33021329 SUPPORT Human Clinical

"Furthermore, one case of GCTB and one case of recurrent GCTB showed positive G34W immunostaining results despite being negative for the genetic mutation."

Demonstrates in human tissue that stain and sequence can disagree, which is why sequencing rather than immunohistochemistry is the discriminating readout proposed here.

Show evidence (1 reference)

PMID:41908959 SUPPORT Model Organism

"The final diagnosis was a primary lumbar extradural giant cell tumor of bone."

Establishes the canine case that would supply the material for this experiment. PARTIAL because the abstract does not report the immunohistochemistry that motivates it.

Show evidence (1 reference)

PMID:41908959 SUPPORT Model Organism

"The final diagnosis was a primary lumbar extradural giant cell tumor of bone."

Establishes the diagnosis in the animal. PARTIAL because the abstract does not report the G34W immunohistochemistry on which the mismatch rests; that appears in the report body.

Does neoadjuvant denosumab increase the risk of local recurrence after subsequent curettage, and if so, is that an artefact of indication bias or a real consequence of leaving mutant stroma in a drug-induced quiescent state?

CONTROVERSY OPEN gctb_denosumab_recurrence_after_withdrawal

Attached to

pathophysiology#Stromal RANKL Overexpression pathophysiology#Local Recurrence After Incomplete Removal

The mechanism predicts the problem. Denosumab acts on RANKL, depleting the reactive osteoclast compartment; in cell-line work it neither inhibits the growth of nor kills the neoplastic stromal cells, and it does not alter their RANKL or OPG expression. The compartment that carries the driver mutation is therefore untouched, and the new bone the drug induces may make residual tumor harder to identify and clear at surgery. Reported recurrence after denosumab-then-surgery ranges from 20% to 100% across a systematic review - a spread wide enough to be uninformative on its own, and one that could equally reflect indication bias, since the drug is given to the worst tumors. Resolving this needs a design that controls for baseline tumor severity, which no published study has.

Show evidence (4 references)

PMID:24060052 SUPPORT In Vitro

"In contrast, denosumab only exerted a minimal inhibitory effect in one cell line and did not induce any apoptosis."

Establishes that the drug does not kill the neoplastic stromal cells, the mechanistic basis of the recurrence concern.

PMID:24060052 SUPPORT In Vitro

"Our findings provide new insights in the anti-tumor effect of denosumab on GCT stromal cells and raise a concern that tumor recurrence may occur after the withdrawal of the drug."

The authors state the withdrawal-recurrence concern that this discussion records.

PMID:32541321 SUPPORT Other

"Concerns have arisen that recurrence rates would be higher than after conventional treatment, ranging from 20 to 100% in a systematic review, although this may be because of bias."

Gives both the reported range and the bias caveat, which is why this is recorded as an open controversy rather than a settled effect. Evidence source is OTHER because this is a review article.

+ 1 more reference

What inherited factor predisposes to giant cell tumor arising in Paget disease of bone, and does that subset share the H3-3A G34W driver curated for conventional sporadic GCTB?

KNOWLEDGE GAP OPEN gctb_paget_associated_familial_subset

Attached to

pathophysiology#Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells

This entry models conventional sporadic GCTB and asserts no inheritance. A distinct subset contradicts that framing at the level of the disease name, and is recorded here rather than silently dropped. Giant cell tumor arising in Paget disease clusters strongly in families, is disproportionately multifocal, favours flat bones over the long-bone epiphyses this entry describes, and carries roughly 50 percent five-year mortality against 0 to 5 percent for GCT without Paget disease. The predisposition is most plausibly inherited through Paget disease genetics rather than through anything in the mechanism graph curated here, but the retrieved literature does not establish the germline basis of the GCT phenotype specifically, and does not report whether these tumors carry H3-3A G34W at all. Until that is known it is not possible to say whether PDB-associated GCT is the same disease arising on a permissive background, or a mechanistically separate entity sharing a histological name - which is why it is scoped out of this entry rather than merged into it, and why a separate entry would be the right home for it.

Proposed experiments

H3-3A genotyping and germline sequencing of PDB-associated giant cell tumors

gctb_pdb_associated_driver_and_germline

Genotype H3-3A codon 34 in a series of PDB-associated giant cell tumors and sequence germline DNA from affected kindreds, to determine whether the subset shares the sporadic driver and whether a segregating predisposition allele accounts for the familial clustering.

Readouts

H3-3A codon 34 mutation status in PDB-associated giant cell tumors

Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells

Direction: UNCHANGED

Interpretation: Wild-type codon 34 would establish PDB-associated GCT as a mechanistically distinct entity; G34W would place it on the same pathograph with an inherited permissive background. Direction is recorded as UNCHANGED because the entity-separating result is the wild-type one.

Show evidence (1 reference)

PMID:33021329 SUPPORT Human Clinical

"Sanger DNA sequencing analysis was used to detect H3F3A mutations."

The established assay this readout would apply to the PDB-associated subset.

Show evidence (3 references)

PMID:25196811 SUPPORT Human Clinical

"Patients with Paget's bone disease (PDB) have an increased risk of developing giant cell tumor (GCT)."

Establishes the existence of the subset this discussion scopes out.

PMID:25196811 SUPPORT Human Clinical

"The mortality rate of PDB-GCT patients was higher than those occurring in GCT patients without PDB (about 50% versus 0% to 5% at 5 years)"

Quantifies the prognostic gulf between the subset and conventional GCTB, the strongest argument that the two should not be modeled as one entry.

PMID:25196811 SUPPORT Human Clinical

"one-fourth of them (24.8%) had multifocal GCTs"

Documents the multifocality that distinguishes the subset from the typically monostotic sporadic disease.

⚙

Pathophysiology

Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells

The initiating and, in conventional GCTB, essentially the only recurrent genetic lesion is a somatic missense mutation at codon 34 of histone H3.3, canonically H3-3A (H3F3A) c.103G>T p.Gly34Trp. Critically for everything downstream, the mutation is confined to the mononuclear mesenchymal stromal cell population and is absent from the osteoclast-like giant cells and their myelomonocytic precursors: the cells that give the tumor its name are not the tumor. Rarer substitutions at the same codon (G34L, G34V, G34R) account for a small remainder of cases.

Neoplastic mesenchymal stromal cell CL:0000134

Experimental models

CRISPR-Cas9 H3.3 G34W-edited GCTB tumor-derived cells CELL LINE Directly manipulates the driver allele, establishing that G34W is necessary for tumor formation rather than merely associated with it.

Animal models

Naturally occurring canine vertebral giant cell tumor of bone Dog fails to recapitulate Immunohistochemistry with the H3.3 G34W mutation-specific antibody showed no nuclear reactivity in the canine tumor. The animal reproduces the disease's cellular architecture without demonstrating the molecular driver that defines it in humans, so it cannot serve as a model of the oncohistone mechanism curated at this node.

Downstream

Genome-Wide Epigenetic Reprogramming by Mutant Histone H3.3 Mutant H3.3 is incorporated into chromatin and perturbs the histone-mark landscape from within the nucleosome.

Show evidence (4 references)

PMID:24162739 SUPPORT Human Clinical

"in 92% (49/53) of giant cell tumors of bone, we found histone H3.3 alterations exclusively in H3F3A, leading to p.Gly34Trp or, in one case, p.Gly34Leu alterations"

Establishes the H3F3A G34 substitution, predominantly G34W, as the near-universal recurrent driver of GCTB.

PMID:24162739 SUPPORT Human Clinical

"The mutations were restricted to the stromal cell population and were not detected in osteoclasts or their precursors."

Directly localizes the driver mutation to the stromal compartment and excludes the giant cells, which is the mechanistic premise of every downstream node in this entry.

PMID:32967858 SUPPORT In Vitro

"Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3 G34W is necessary for tumor formation."

CRISPR-Cas9 editing of patient-derived cells establishes that G34W is not merely a marker but is required for tumor formation.

+ 1 more reference

Genome-Wide Epigenetic Reprogramming by Mutant Histone H3.3

Incorporated H3.3-G34W acts in cis on its own tail - the bulky tryptophan at position 34 impairs H3K36 trimethylation of the mutant histone - and the consequences propagate genome-wide. The repressive H3K27me3 mark is redistributed from intergenic to genic regions, and DNA methylation, chromatin accessibility, and other histone modifications shift with it, most markedly over heterochromatic and bivalent domains. The result is aberrant transcription across a broad program rather than dysregulation of a single target gene.

Chromatin remodeling GO:0006338 ⚠ ABNORMAL Heterochromatin organization GO:0070828 ⚠ ABNORMAL

Experimental models

Patient-derived GCTB stromal cell culture PRIMARY CELL CULTURE Reproduces the chromatin incorporation of mutant H3.3 and the genome-wide DNA methylation, accessibility, and histone-mark changes in cells carrying the endogenous mutation.

Downstream

Arrested Osteogenic Differentiation of the Neoplastic Stroma Aberrant transcription redirects mesenchymal cell fate away from mature osteoblastic differentiation.

Enhancer-Level SCUBE3 Repression Mutant-H3.3 enrichment and altered histone marks at SCUBE3 enhancers silence a paracrine restraint on osteoclast recruitment.

Show evidence (3 references)

PMID:32967858 SUPPORT In Vitro

"we show that H3.3K36me3 loss on mutant H3.3 alters the deposition of the repressive H3K27me3 mark from intergenic to genic regions, beyond areas of H3.3 deposition"

States the specific chromatin-mark redistribution that defines this node, including its spread beyond sites of mutant H3.3 deposition.

PMID:33110075 SUPPORT In Vitro

"in patient-derived stromal cells H3.3-G34W is incorporated into the chromatin and associates with massive epigenetic alterations on the DNA methylation, chromatin accessibility and histone modification level"

Independently confirms genome-wide, multi-layer epigenetic disruption in patient-derived stromal cells.

PMID:33110075 SUPPORT In Vitro

"These epigenetic alterations affect mainly heterochromatic and bivalent regions and provide possible explanations for the genomic instability, as well as the osteolytic phenotype of GCTB."

Localizes the changes to heterochromatic and bivalent domains and links them to the osteolytic phenotype curated downstream.

Arrested Osteogenic Differentiation of the Neoplastic Stroma

The mutation arises in a differentiating mesenchymal stem cell and holds it short of mature osteoblast identity. Mutant stromal cells retain proliferative capacity while failing to complete osteogenic differentiation, tracing a neoplastic trajectory from an SPP1-positive osteoblast-like progenitor state toward an ACTA2-positive myofibroblast-like state that secretes the matrix ligands recruiting osteoclasts. This is the neoplastic compartment of the tumor, and it is histologically the least conspicuous.

Osteoblast-like mesenchymal progenitor CL:0000134

Osteoblast differentiation GO:0001649 ↓ DECREASED Stromal cell proliferation GO:0008283 ↑ INCREASED

Experimental models

Patient-derived GCTB stromal cell culture PRIMARY CELL CULTURE Mutant patient-derived cells show impaired osteogenic differentiation under differentiation conditions.

Downstream

Stromal RANKL Overexpression The arrested, transformed stroma expresses RANKL and monocyte-recruiting chemokines at levels that drive osteoclastogenesis.

Malignant Sarcomatous Transformation A small minority of these neoplastic stromal populations acquire additional TP53 or telomerase alterations and progress to a high-grade sarcoma.

Show evidence (4 references)

PMID:33110075 SUPPORT In Vitro

"The mutation occurs in differentiating mesenchymal stem cells and associates with an impaired osteogenic differentiation."

Identifies the cell of origin as a differentiating mesenchymal stem cell and the differentiation block that defines this node.

PMID:32967858 SUPPORT In Vitro

"This promotes redistribution of other chromatin marks and aberrant transcription, altering cell fate in mesenchymal progenitors and hindering differentiation."

Connects the upstream epigenetic node to the altered mesenchymal cell fate and differentiation block curated here.

PMID:32967858 SUPPORT In Vitro

"Single-cell transcriptomics reveals that H3.3 G34W stromal cells recapitulate a neoplastic trajectory from a SPP1+ osteoblast-like progenitor population toward an ACTA2+ myofibroblast-like population, which secretes extracellular matrix ligands predicted to recruit and activate osteoclasts."

Provides the single-cell resolved identity of the neoplastic stromal compartment and its link to osteoclast recruitment.

+ 1 more reference

Enhancer-Level SCUBE3 Repression

Among the transcriptional consequences of the oncohistone, one has been resolved to a specific paracrine mediator. Mutant H3.3 is enriched at the enhancer regions of SCUBE3, which encodes a secreted TGF-beta-like factor, and the accompanying histone-mark changes reduce its expression. Loss of stromal SCUBE3 removes a brake on osteoclast recruitment, so this node is a de-repression step rather than an activating one - the tumor recruits osteoclasts partly by ceasing to restrain them.

Positive regulation of osteoclast differentiation GO:0045672 ↑ INCREASED

Experimental models

Monocyte osteoclastogenesis co-culture with GCTB stromal cells CO CULTURE Quantifies osteoclast formation as a function of stromal SCUBE3, the readout that establishes SCUBE3 as a restraint rather than a bystander.

Downstream

Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells Loss of the SCUBE3 restraint permits greater osteoclast recruitment to the tumor site.

Show evidence (2 references)

PMID:36138226 SUPPORT In Vitro

"We show that the changes in the transcriptome and epigenome in the mesenchymal cells caused by the H3.3-G34W mutation contribute to increase osteoclast recruitment in part via reduced expression of the TGFβ-like soluble factor, SCUBE3."

States the causal chain from the oncohistone through reduced SCUBE3 to increased osteoclast recruitment that this node represents.

PMID:36138226 SUPPORT In Vitro

"Transcriptional changes in SCUBE3 are associated with altered histone marks and H3.3G34W enrichment at its enhancer regions."

Provides the enhancer-level chromatin mechanism linking mutant H3.3 occupancy to SCUBE3 repression.

Stromal RANKL Overexpression

The neoplastic stromal cells express RANKL (TNFSF11), the master differentiation and survival signal for the osteoclast lineage, alongside monocyte-recruiting chemokines such as SDF-1 and MCP-1 and pro-osteoclastic cytokines including IL-6 and TNF. RANKL engages RANK on myelomonocytic precursors that the tumor has recruited. This is the therapeutically actionable step: it is the node that denosumab occupies.

Neoplastic mesenchymal stromal cell CL:0000134

Osteoclast differentiation GO:0030316 ↑ INCREASED

Downstream

Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells RANKL-RANK engagement drives differentiation and fusion of recruited monocytic precursors into multinucleated osteoclasts.

Show evidence (3 references)

PMID:20149736 SUPPORT Human Clinical

"GCT is rich in osteoclast-like giant cells and contains mononuclear (stromal) cells that express RANK ligand (RANKL), a key mediator of osteoclast activation."

Attributes RANKL expression specifically to the mononuclear stromal cells and names it the key mediator of osteoclast activation.

PMID:29944971 SUPPORT Other

"mononuclear stromal cells in GCTB express fundamental RANKLs and various chemokines and cytokines associated with monocyte recruitment"

Confirms that the stromal compartment supplies both RANKL and the monocyte-recruiting signals feeding the osteoclast pool. Evidence source is OTHER because this is a review article.

PMID:22662295 SUPPORT Other

"Pro-osteoclastogenic cytokines such as receptor activator of nuclear factor kappa-B ligand (RANKL), interleukin (IL)-6, and tumor necrosis factor (TNF) as well as monocyte-recruiting chemokines such as stromal cell-derived factor-1 (SDF-1) and monocyte chemoattractant protein (MCP)-1 participate..."

Enumerates the wider cytokine and chemokine program accompanying RANKL in driving osteoclastogenesis and bone destruction. Evidence source is OTHER because this is a review article.

Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells

Monocyte-macrophage lineage precursors recruited into the lesion differentiate and fuse into the enormous multinucleated osteoclast-like giant cells, frequently carrying more than fifty nuclei, that dominate the tumor histologically and supply its name. These cells carry no driver mutation: they are a reactive population induced by the neoplastic stroma. Additional stromal products, including the proteoglycan serglycin, promote the same differentiation step.

Osteoclast-like multinucleated giant cell CL:0000092 Recruited monocytic precursor CL:0000576

Syncytium formation by cell-cell fusion GO:0000768 ↑ INCREASED

Animal models

Naturally occurring canine vertebral giant cell tumor of bone Dog recapitulates The canine tumor contains the same tripartite cellular composition as the human disease, with abundant osteoclast-type multinucleated giant cells distributed among mononuclear stromal and histiocytic populations.

Downstream

Excessive Osteoclastic Bone Resorption The expanded osteoclast pool resorbs mineralized matrix far in excess of replacement.

Osteoclast-Derived SEMA4D Feedback onto the Mutant Stroma Activated osteoclasts secrete SEMA4D, closing a paracrine loop back onto the neoplastic compartment.

Show evidence (3 references)

PMID:34556636 SUPPORT In Vitro

"Giant cell tumor of bone (GCTB) is an aggressive osteolytic bone tumor characterized by the within-tumor presence of osteoclast-like multinucleated giant cells (MGCs), which are induced by the neoplastic stromal cells and lead to extensive bone destruction."

States that the giant cells are induced by the neoplastic stroma and that they are the proximate cause of bone destruction.

PMID:34556636 SUPPORT In Vitro

"Stromal-derived SRGN promotes osteoclast differentiation from monocytes."

Identifies serglycin as an additional stromal factor driving the monocyte-to-osteoclast transition curated at this node.

PMID:36138226 SUPPORT In Vitro

"Giant cell tumours of bone (GCTs) are characterised by a mutated histone H3.3 as the sole genetic driver present in bone-forming osteoprogenitor cells but absent from abnormally large bone-resorbing osteoclasts which represent the hallmark of these neoplasms."

Confirms that the hallmark giant cells lack the driver mutation and are therefore reactive rather than neoplastic.

Osteoclast-Derived SEMA4D Feedback onto the Mutant Stroma

The stroma-to-osteoclast axis is not one-way. Osteoclasts in GCTB secrete unregulated amounts of SEMA4D, which enhances proliferation of the mutant osteoprogenitors while arresting their maturation - reinforcing the very differentiation block that generated the osteoclast pool. The loop makes the neoplastic stroma partly dependent on the reactive compartment it creates, and this dependency is what makes depleting osteoclasts a therapeutically meaningful intervention rather than a purely symptomatic one.

Osteoclast-like multinucleated giant cell CL:0000092

Downstream

Arrested Osteogenic Differentiation of the Neoplastic Stroma SEMA4D feeds back onto the neoplastic stroma, sustaining proliferation and the maturation block. This is a deliberate feed-forward cycle in the pathograph, not a curation error.

Show evidence (2 references)

PMID:36138226 SUPPORT In Vitro

"In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances proliferation of mutated osteoprogenitors arresting their maturation."

States the reverse arm of the paracrine loop, both the proliferative effect and the maturation arrest, exactly as curated here.

PMID:36138226 SUPPORT In Vitro

"These findings provide a mechanism by which GCTs undergo differentiation in response to denosumab, a drug that depletes the tumour of osteoclasts."

Links the feedback loop to the observed stromal differentiation seen when osteoclasts are depleted by denosumab, supporting the loop's therapeutic relevance.

Excessive Osteoclastic Bone Resorption

The recruited osteoclast pool degrades mineralized matrix at a rate the arrested, non-differentiating stroma cannot replace with new bone. Because the stroma is held short of mature osteoblast identity, the formative arm of remodeling is simultaneously suppressed, so resorption is uncoupled in both directions at once. This is the shared effector step this entry has in common with metabolic bone disease, and the reason the tumor's radiographic signature is purely lytic.

Osteoclast-like multinucleated giant cell CL:0000092

Bone resorption GO:0045453 ↑ INCREASED Bone remodeling GO:0046849 ↕ DYSREGULATED

Downstream

Locally Aggressive Osteolytic Tumor Mass Sustained resorption produces the expanding, cortex-thinning lytic lesion.

Show evidence (2 references)

PMID:22662295 SUPPORT Other

"A diverse array of inflammatory cytokines and chemokines disrupts osteoblastic differentiation and promotes the formation of excessive multi-nucleated osteoclastic cells."

Captures both arms of the uncoupling curated here, suppressed osteoblastic differentiation alongside excessive osteoclast formation. Evidence source is OTHER because this is a review article.

PMID:20149736 SUPPORT Human Clinical

"Giant-cell tumour (GCT) of bone is a primary osteolytic bone tumour with low metastatic potential and is associated with substantial skeletal morbidity."

Establishes the osteolytic character and skeletal morbidity that follow from unopposed resorption.

Locally Aggressive Osteolytic Tumor Mass

The combined neoplastic and reactive compartments form an expanding epiphyseal-metaphyseal mass that erodes trabecular bone, thins and expands the cortex, and in advanced (Campanacci grade III) disease breaches it into the surrounding soft tissue. Subchondral extension threatens the adjacent joint. Secondary aneurysmal-bone-cyst-like change with blood-filled spaces is a common accompaniment. The mass, not any systemic effect, causes the disease's clinical phenotype: pain, swelling, restricted joint motion, pathologic fracture, and - in axial lesions - neural compression.

Downstream

Local Recurrence After Incomplete Removal Residual mutant stroma left in the cavity after intralesional surgery regenerates the lesion.

Pulmonary Implantation of Histologically Benign Tumor A minority of tumors seed the lung, most strongly associated with local recurrence, high Campanacci stage, and curettage rather than resection.

Show evidence (2 references)

PMID:29987945 SUPPORT Human Clinical

"Giant cell tumors of bone (GCT-B) are rare, locally aggressive tumors characterized by an abundance of giant cells."

Characterizes the lesion as locally aggressive with abundant giant cells, the tissue-level outcome curated at this node.

PMID:29987945 SUPPORT Human Clinical

"Most common localization was the femur (35%), followed by the tibia (18%)."

Gives the nationwide-registry anatomical distribution of the tumor mass.

Local Recurrence After Incomplete Removal

Because the neoplastic stromal cells are histologically inconspicuous and diffusely distributed through the cavity wall, intralesional curettage reliably leaves some behind, and the tumor regrows. Recurrence is the dominant clinical problem in GCTB and the reason for high-speed burring, chemical or physical adjuvants, and cementation. It also raises the risk of the two rarer downstream outcomes, pulmonary implantation and malignant transformation.

Downstream

Pulmonary Implantation of Histologically Benign Tumor Repeated recurrence is among the strongest identified risk factors for lung involvement.

Show evidence (3 references)

PMID:39236154 SUPPORT Human Clinical

"The overall rate of recurrence for GCTB after intralesional curettage with BC was 20.05% vs. 29.74% with BG"

Quantifies post-curettage recurrence in a 1,454-patient meta-analysis for both cavity-filling strategies.

PMID:21301899 SUPPORT Human Clinical

"The median interval between initial surgery and the first recurrence of GCT was 16 months (2-180 months)."

Gives the timing of recurrence, supporting the surveillance interval implied by this node.

PMID:21301899 SUPPORT Human Clinical

"Repeat recurrence also correlates with lung metastasis."

Supports the curated edge from recurrence toward pulmonary implantation.

Pulmonary Implantation of Histologically Benign Tumor

A minority of GCTBs produce lung nodules that are histologically identical to the primary tumor yet behave nothing like carcinomatous metastasis: survival remains near-normal, and spontaneous regression has been documented. Whether these represent true metastasis or mechanical embolization of tumor fragments during surgical manipulation is unresolved, which is why the curated confidence is PROVISIONAL and the node is named for implantation rather than metastasis. The observed risk factors - local recurrence, high Campanacci stage, and curettage over resection - are equally compatible with either reading.

Show evidence (3 references)

PMID:28443231 SUPPORT Human Clinical

"The recurrence rate, Campanacci stage, and surgical method were significant risk factors for lung metastasis."

Identifies the three risk factors curated in this node's description.

PMID:28443231 SUPPORT Human Clinical

"The 5-year overall survival rate was 94.4%."

Quantifies the indolent behavior that distinguishes these deposits from conventional malignant metastasis.

PMID:21301899 SUPPORT Human Clinical

"The incidence of lung metastasis and malignant transformation were 7.5% (8 out of 107 patients) and 2.7% (3 out of 110 patients), respectively."

Provides cohort frequencies for both rare outcomes curated in this entry.

Malignant Sarcomatous Transformation

Rarely, GCTB progresses to a high-grade sarcoma, either arising alongside a conventional component (primary malignant GCTB) or years after treatment of a conventional tumor (secondary malignant GCTB). Transformation requires genetic events beyond the oncohistone: TP53 mutation with p53 nuclear accumulation, and loss of H3K27me3, are each found in subsets and appear mutually exclusive. Telomerase alterations are a distinct route, and carry a specific therapeutic implication - they render the neoplastic cells independent of osteoclasts for proliferation, predicting denosumab unresponsiveness. In a substantial fraction of cases the malignant component has lost the H3-3A G34W mutation the benign component carried, so the transformed tumor is not simply a more aggressive version of its precursor.

Show evidence (4 references)

PMID:34785767 SUPPORT Human Clinical

"NGS on four MGCTBs revealed pathogenic mutations in TP53 (n = 3), EZH2 (n = 1) and several other genes."

Identifies the additional driver alterations found in malignant transformation.

PMID:34785767 SUPPORT Human Clinical

"The results suggested that p53 alteration and dysfunction of histone methylation as evidenced by H3K27me3 loss may play an important role in the malignant progression of GCTB"

States the two mechanistic routes to malignant progression curated at this node, with the authors' own hedging preserved.

PMID:31285528 SUPPORT Human Clinical

"However, in the remaining five cases, in contrast to their associated H3F3A G34W-mutant giant cell tumor, the sarcoma lacked the H3F3A G34W mutation, either entirely or sub-clonally in the samples tested."

Documents loss of the founding driver in the malignant component, the basis for the claim that transformation is not simple progression.

+ 1 more reference

✶

Histopathology

Osteoclast-Like Multinucleated Giant Cells on a Mononuclear Background

The diagnostic histology is a uniform distribution of very large multinucleated osteoclast-like giant cells, often with dozens of nuclei, scattered evenly through sheets of mononuclear cells. The mononuclear population is itself two populations that light microscopy does not separate: reactive monocyte-macrophage lineage cells, and the spindled neoplastic stromal cells that carry the mutation. Even distribution of the giant cells is a useful discriminator from other giant-cell-rich lesions, where they tend to cluster.

Show evidence (2 references)

PMID:29987945 SUPPORT Human Clinical

"Giant cell tumor of bone (GCT-B) is a locally aggressive neoplasm composed of sheets of mononuclear cells admixed with uniformly distributed large osteoclast-like giant cells, primarily affecting the metaphysis of long bones"

Describes the sheets of mononuclear cells with uniformly distributed giant cells that define the histology.

PMID:23378375 SUPPORT Other

"Mononuclear stromal cells are the physiologically active and diagnostic cell type."

Identifies the mononuclear stromal cell rather than the giant cell as the biologically decisive population. Evidence source is OTHER because this is a review article.

H3.3 G34W Mutant-Protein Immunoreactivity

Nuclear staining with a mutation-specific antibody in the neoplastic mononuclear cells, absent from the giant cells - immunohistochemistry that directly visualizes the compartment restriction of the driver. It has become the practical diagnostic discriminator against giant-cell-rich mimics. Discordance in both directions exists: rare tumors stain positive without a detectable mutation, and sequencing can be falsely negative when neoplastic cells are sparse in the sample.

Show evidence (3 references)

PMID:33021329 SUPPORT Human Clinical

"Immunohistochemistry showed that GCTBs harboring G34W also expressed the mutant protein in tumor cell nuclei."

Establishes concordance between the mutation and nuclear mutant-protein staining in tumor cells.

PMID:33021329 SUPPORT Human Clinical

"Although DNA sequencing analysis detected rare mutation types of H3F3A, false-negative results were also present due to the small number of cells in the samples."

Documents the sequencing false-negative mode caused by low neoplastic-cell content. Recorded as PARTIAL because it qualifies the assay rather than supporting it.

PMID:35837707 SUPPORT Other

"The most frequent mutation (G34W) can be detected using immunohistochemistry and is highly specific in differentiating GCTB from other giant cell containing tumors."

Supports the diagnostic discriminating role of the immunohistochemical stain. Evidence source is OTHER because this is a review article.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Metabolism 1

Local Swelling and Joint Effusion Joint swelling HP:0001386

Show evidence (1 reference)

PMID:23378375 SUPPORT Other

"Most patients present with pain, swelling, joint effusion, and disability in the third and fourth decades of life."

Names swelling and joint effusion among the usual presenting findings. Evidence source is OTHER because this is a review article.

Musculoskeletal 2

Pathologic Fracture HP:0002756

Show evidence (1 reference)

PMID:21139931 SUPPORT Human Clinical

"Patients with GCT of bone typically present with mechanical difficulty and pain as a result of bone destruction and are at an increased risk for fracture."

States the increased fracture risk arising from tumor-mediated bone destruction.

Limitation of Joint Mobility HP:0001376

Show evidence (1 reference)

PMID:28905737 SUPPORT Other

"Clinical symptoms are nonspecific and may include local pain, swelling, and limited range of motion of the adjacent joint."

Directly names limited range of motion of the adjacent joint among the presenting symptoms. Evidence source is OTHER because this is a review.

Constitutional 1

Localized Bone Pain HP:0002653

Temporal: CHRONIC Course: PROGRESSIVE

No frequency band is asserted. Pain is described as the typical presenting symptom in every source consulted, but none of the cached abstracts reports a proportion, and a FrequencyEnum value would be a quantitative claim the evidence does not make.

Show evidence (2 references)

PMID:21139931 SUPPORT Human Clinical

"Patients with GCT of bone typically present with mechanical difficulty and pain as a result of bone destruction and are at an increased risk for fracture."

Attributes the presenting pain and mechanical difficulty directly to bone destruction, and links it to fracture risk.

PMID:28905737 SUPPORT Other

"Clinical symptoms are nonspecific and may include local pain, swelling, and limited range of motion of the adjacent joint."

Names local pain first among the presenting symptoms. Evidence source is OTHER because this is a review article.

Other 5

Giant Cell Tumor of Bone OBLIGATE HP:0011847

Show evidence (1 reference)

PMID:29987945 SUPPORT Human Clinical

Describes the defining lesion and its characteristic long-bone location.

Pulmonary Nodules HP:0033608

Show evidence (1 reference)

PMID:28443231 SUPPORT Human Clinical

"Eighteen patients had unilateral metastasis and 28 had bilateral metastasis. Most lesions (n=38) were located in the peripheral lung."

Describes the laterality and peripheral distribution of the pulmonary deposits curated here.

Secondary Sarcoma HP:0100242

Show evidence (1 reference)

PMID:21301899 SUPPORT Human Clinical

"The incidence of lung metastasis and malignant transformation were 7.5% (8 out of 107 patients) and 2.7% (3 out of 110 patients), respectively."

Reports the frequency of malignant transformation in a recurrent-GCT cohort.

Secondary Aneurysmal Bone Cyst Change HP:0012063

Show evidence (3 references)

PMID:23708046 SUPPORT Human Clinical

"MRI demonstrates a multiloculated lesion in the distal femur with multiple fluid-fluid levels and cortical penetration of the lesion."

Human case documenting the multiple fluid-fluid levels that are the radiological signature of secondary aneurysmal bone cyst change within a giant cell tumor.

PMID:21139758 SUPPORT Other

"Giant cell tumor can produce wide-ranging appearances depending on site, complications such as hemorrhage or pathological fracture and after surgical intervention."

Imaging review noting that haemorrhagic complication changes the tumor's appearance, the general phenomenon of which secondary aneurysmal bone cyst change is the specific form. Evidence source is OTHER because this is a review article.

PMID:41908959 SUPPORT Model Organism

"Both masses exhibited whitish areas interspersed with blood-filled spaces."

The same blood-filled cystic change in the naturally occurring canine disease, recorded as a second, species-labelled observation rather than as the sole support for a human phenotype. Evidence source is MODEL_ORGANISM because the observation is in a dog.

Spinal Cord or Nerve Root Compression Spinal cord compression HP:0002176

Show evidence (3 references)

PMID:21045974 SUPPORT Human Clinical

"Most patients presented with pain or neurologic deficit at the site of tumor involvement, and symptoms were usually present for many months prior to diagnosis."

Human series of 23 spinal and sacral giant cell tumors reporting neurological deficit as a usual presenting feature, with the insidious time course curated in this description.

PMID:29745092 SUPPORT Human Clinical

"A system (MUD system) proposed by our center was applied to score the sacral nerve deficit changes before surgery in group 3."

A sacral giant cell tumor cohort in which nerve deficit is a scored clinical endpoint of neoadjuvant denosumab, supporting both the phenotype and the treatment rationale that depends on it.

PMID:41908959 SUPPORT Model Organism

"Necropsy findings confirmed the presence of a nodular soft mass below the left kidney and a firm mass compressing the medullary canal at L1-L3."

An explicit anatomical demonstration of neural-canal compression by a vertebral giant cell tumor, retained as a second observation alongside the human series. Evidence source is MODEL_ORGANISM because this is the canine case.

🧬

Genetic Associations

H3-3A

Gene: H3-3A hgnc:4764 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:24162739 SUPPORT Human Clinical

"The mutations were restricted to the stromal cell population and were not detected in osteoclasts or their precursors."

Establishes the somatic, stroma-restricted nature of the driver that this genetic entry records.

PMID:32967858 SUPPORT In Vitro

"Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3 G34W is necessary for tumor formation."

Demonstrates by genome editing that the variant is required for tumor formation, supporting SOMATIC_DRIVER rather than a bystander annotation.

Variants (1)

H3-3A c.103G>T p.Gly34Trp

MISSENSE

The canonical oncohistone substitution. It does not raise the activity of a normal H3.3 function; it creates a chromatin behaviour wild-type H3.3 does not have - impaired H3K36 trimethylation in cis and consequent genome-wide redistribution of H3K27me3 - so it is best read as neomorphic rather than as a simple gain of function.

Show evidence (1 reference)

PMID:32967858 SUPPORT In Vitro

"we show that H3.3K36me3 loss on mutant H3.3 alters the deposition of the repressive H3K27me3 mark from intergenic to genic regions, beyond areas of H3.3 deposition"

Describes the specific chromatin consequence of the substitution that makes it neomorphic rather than merely hyperactive.

TP53

Gene: TP53 hgnc:11998 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:34785767 SUPPORT Human Clinical

"Immunohistochemical analysis of the nine MGCTBs confirmed the p53 nuclear accumulation (n = 5) and loss of H3K27me3 expression (n = 3) and showed that they were mutually exclusive."

Documents both progression routes and their mutual exclusivity in malignant giant cell tumor of bone.

TERT

Gene: TERT hgnc:11730 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:36138226 SUPPORT In Vitro

"In contrast, hTERT alterations, commonly found in malignant GCT, result in the histone-mutated neoplastic cells being independent of osteoclasts for their proliferation, predicting unresponsiveness to denosumab."

States both the association with malignant GCT and the loss of osteoclast dependence that carries the therapeutic implication.

TNFSF11

Gene: TNFSF11 hgnc:11926 relationship_type: BIOMARKER

Show evidence (1 reference)

PMID:20149736 SUPPORT Human Clinical

"GCT is rich in osteoclast-like giant cells and contains mononuclear (stromal) cells that express RANK ligand (RANKL), a key mediator of osteoclast activation."

Records stromal RANKL expression, the basis for treating this gene as a mechanistic and therapeutic marker rather than a mutated driver.

SCUBE3

Gene: SCUBE3 hgnc:13655 relationship_type: BIOMARKER

Show evidence (1 reference)

PMID:36138226 SUPPORT In Vitro

"Transcriptional changes in SCUBE3 are associated with altered histone marks and H3.3G34W enrichment at its enhancer regions."

Ties reduced SCUBE3 expression to mutant-H3.3 occupancy at its enhancers.

SEMA4D

Gene: SEMA4D hgnc:10732 relationship_type: BIOMARKER

Show evidence (1 reference)

PMID:36138226 SUPPORT In Vitro

"In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances proliferation of mutated osteoprogenitors arresting their maturation."

Documents the osteoclast-derived signal and its effect on the neoplastic compartment.

💊

Medical Actions

Extended Intralesional Curettage with Adjuvant and Cementation

Action: curettage procedure Ontology label: Curettage Procedure NCIT:C15216

The standard operation for most Campanacci grade I and II lesions: curettage of the cavity, high-speed burring of its walls, a chemical or physical adjuvant, and filling with polymethylmethacrylate bone cement or bone graft. It preserves the joint at the cost of a substantial recurrence rate, because the neoplastic stroma is inconspicuous and diffuse. Meta-analytic evidence favours cement over graft for local control, though recurrence remains high either way, and a distal-radius meta-analysis found no cement advantage in that site - so the choice is not settled across all locations.

Mechanism Target:

INHIBITS Locally Aggressive Osteolytic Tumor Mass — Physically removes the tumor mass while preserving the adjacent joint.

Show evidence (1 reference)

PMID:39236154 SUPPORT Human Clinical

"While either bone grafting (BG) or bone cement (BC) can be utilized to fill defects after intralesional curettage, the optimal treatment remains contested."

Describes the procedure acting directly on the tumor cavity, the mass node this link targets.

Show evidence (3 references)

PMID:39236154 SUPPORT Human Clinical

"Intralesional curettage with BG had a recurrence risk ratio of 1.68 (95% confidence interval [CI], 1.22-2.31, p = 0.001) when compared with BC."

Quantifies the cement-versus-graft difference in a 1,454-patient meta-analysis: curettage plus bone graft carries a 68% higher recurrence risk than curettage plus cement.

PMID:39236154 SUPPORT Human Clinical

"However, the rates of recurrence remain substantial for both groups, necessitating careful consideration of the benefits and potential pitfalls associated with BC vs. BG when considering salvage options after recurrences."

Supports the procedure while explicitly qualifying it: recurrence stays substantial regardless of filler, which is why this is PARTIAL.

PMID:22773395 SUPPORT Human Clinical

"The use of PMMA versus bone graft did not affect the recurrence rate (RR, 0.98; 95% CI, 0.44-2.17)."

A distal-radius meta-analysis that did not reproduce the cement advantage, recorded as PARTIAL because it qualifies the general recommendation by anatomical site.

En Bloc Wide Resection

Action: orthopedic surgical procedure Ontology label: Orthopedic Surgical Procedure NCIT:C16186

Complete removal with a margin of normal tissue, giving markedly better local control than curettage at the cost of joint sacrifice and a reconstruction. Reserved for Campanacci grade III lesions, extensively destructive tumors, and some recurrences - the trade is fewer recurrences for more major complications, and the balance shifts with grade.

Mechanism Target:

INHIBITS Local Recurrence After Incomplete Removal — Removing the lesion with a margin eliminates the residual mutant stroma that drives recurrence after intralesional surgery.

Show evidence (1 reference)

PMID:22773395 SUPPORT Human Clinical

Quantifies the recurrence advantage of resection over intralesional excision, largest in high-grade tumors, the effect this mechanism link asserts.

Show evidence (2 references)

PMID:22773395 SUPPORT Human Clinical

"Overall, patients in the intralesional excision group had a higher recurrence rate (relative risk [RR], 2.80; 95% CI, 1.17-6.71), especially for Campanacci grade 3 GCTs (RR, 4.90; 95% CI, 1.36-17.66), yet fewer major complications (RR, 0.21; 95% CI, 0.09-0.54) than the en bloc resection group."

Quantifies both sides of the trade-off, the far higher recurrence risk of intralesional excision overall and for Campanacci grade 3 tumors in particular, and the lower rate of major complications that is its counterweight.

PMID:22773395 SUPPORT Human Clinical

"intralesional excision appears to be more appropriate for the treatment of local lesions (e.g., grades 1 and 2) than grade 3 GCTs of the distal radius"

States the grade-dependent selection rule that assigns resection to higher-grade disease.

Denosumab

Action: Pharmacotherapy NCIT:C15986

Agent: denosumab NCIT:C61313

A fully human monoclonal antibody against RANKL, and the clearest example in this entry of a mechanism-directed therapy. By blocking RANKL it starves the reactive osteoclast compartment, eliminating the giant cells and halting resorption; the arrested stroma then differentiates and new bone forms in the lesion. It permits surgery to be downstaged or deferred in tumors that would otherwise require a morbid operation, and it is the principal option in unresectable axial disease. Two limits follow directly from the mechanism: it does not eliminate the mutant stroma, so tumors regrow when it stops; and tumors that have escaped osteoclast dependence through telomerase alterations are predicted not to respond.

Mechanism Target:

INHIBITS Stromal RANKL Overexpression — Denosumab binds RANKL directly, preventing engagement of RANK on osteoclast precursors. This is the node the drug occupies.

Show evidence (1 reference)

PMID:20149736 SUPPORT Human Clinical

"We investigated the potential therapeutic effect of denosumab, a fully human monoclonal antibody against RANKL, on tumour-cell survival and growth in patients with GCT."

Identifies RANKL as the molecular target of the antibody, matching the curated mechanism node.

INHIBITS Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells — Downstream of RANKL blockade the giant cells are depleted, which is how histological response was defined in the first trial.

Show evidence (1 reference)

PMID:20149736 SUPPORT Human Clinical

"The primary endpoint was tumour response, defined as elimination of at least 90% of giant cells or no radiological progression of the target lesion up to week 25."

Shows that giant cell elimination is the measured effect of the drug, supporting this specific mechanism link.

Show evidence (4 references)

PMID:20149736 SUPPORT Human Clinical

"30 of 35 (86%; 95% CI 70-95) of evaluable patients had a tumour response: 20 of 20 assessed by histology and 10 of 15 assessed by radiology."

Quantifies the response rate in the proof-of-concept phase 2 study.

PMID:26033180 SUPPORT Human Clinical

"At the data cutoff date, most patients had not yet undergone surgery (n = 106; 48 %) or had a less morbid procedure (n = 84; 38 %) than originally planned."

Documents the surgical-downstaging benefit that is the main reason for neoadjuvant use.

PMID:31704134 SUPPORT Human Clinical

"28 (5%) patients had positively adjudicated osteonecrosis of the jaw, four (1%) had atypical femur fracture, and four (1%) had hypercalcaemia occurring 30 days after denosumab discontinuation."

The large phase 2 safety dataset. Recorded as PARTIAL because it reports the toxicity that bounds long-term use rather than efficacy.

+ 1 more reference

Zoledronic Acid

Action: Pharmacotherapy NCIT:C15986

Agent: zoledronic acid CHEBI:46557

A bisphosphonate used as a systemic or cement-loaded local adjuvant. Its mechanism in GCTB is not the same as denosumab's: in cell-line work it directly inhibits growth of and induces apoptosis in the neoplastic stromal cells, whereas denosumab does neither. That difference makes it conceptually attractive as an adjuvant against the compartment denosumab leaves behind, but the clinical evidence is small-trial and meta-analytic rather than definitive, so it is curated as a supported adjunct and not as standard of care.

Mechanism Target:

INHIBITS Arrested Osteogenic Differentiation of the Neoplastic Stroma — Zoledronic acid acts on the neoplastic stromal compartment itself, inhibiting growth and inducing apoptosis in cell lines - the compartment that RANKL blockade does not touch.

Show evidence (1 reference)

PMID:24060052 SUPPORT In Vitro

"ZOL was found to exhibit a dose-dependent inhibition in cell growth in all GCT stromal cell lines tested and cause apoptosis in two out of three cell lines."

Demonstrates a direct anti-stromal effect, the basis for targeting this mechanism node rather than the RANKL node.

Show evidence (2 references)

PMID:32541321 SUPPORT Other

"Also, the bisphosphonate zoledronic acid has activity in GCTB by directly targeting the neoplastic stromal cells."

States the drug's activity and its stromal target. Evidence source is OTHER because this is a review article.

PMID:32541321 SUPPORT Other

"In a small RCT, bisphosphonates were successful in controlling tumour growth and a higher apoptotic index of tumour cells was seen after zoledronic acid versus controls."

The clinical support is a small randomized trial, so this is recorded as PARTIAL rather than SUPPORT. Evidence source is OTHER because the citing article is a review.

Radiation Therapy

Action: radiation therapy Ontology label: Radiation Therapy NCIT:C15313

Reserved for tumors that cannot be resected and where denosumab, bisphosphonates, and embolization are unavailable or have failed - largely spinal and sacral disease. The reason for that narrow indication is mechanistic rather than merely one of efficacy: irradiation is itself associated with later sarcomatous transformation of a tumor whose baseline transformation risk is already the most feared outcome.

Mechanism Target:

INHIBITS Locally Aggressive Osteolytic Tumor Mass — Achieves local control of an unresectable mass.

Show evidence (1 reference)

PMID:21139931 SUPPORT Human Clinical

"Malignant giant cell tumor (GCT) of bone is a rare tumor with debilitating consequences."

Establishes the severity of the malignant outcome that motivates restricting radiotherapy. Recorded as PARTIAL because it characterizes the risk this treatment is limited by, not the treatment's efficacy.

Embolization Therapy

Action: embolization therapy Ontology label: Embolization Therapy NCIT:C15230

Selective arterial embolization, used preoperatively to reduce blood loss during surgery on a highly vascular tumor and, in some inoperable axial lesions, as a primary modality.

Mechanism Target:

INHIBITS Locally Aggressive Osteolytic Tumor Mass — Devascularizes the tumor mass.

Show evidence (1 reference)

PMID:21045974 SUPPORT Human Clinical

"One sacral GCT patient was treated only with serial arterial embolization with good disease control."

Embolization alone controlled the tumor mass in a patient who received no other treatment, the clearest available demonstration that devascularization acts on this node rather than merely assisting surgery.

Show evidence (2 references)

PMID:21045974 SUPPORT Human Clinical

"Six of the sacral GCT patients were treated with pre-operative arterial embolization and intralesional surgical resection, and two developed a recurrence."

Documents the preoperative-adjunct use of embolization in sacral disease, the setting in which this treatment is standard practice.

PMID:21045974 SUPPORT Human Clinical

"conservative therapy involving arterial embolization and intralesional resection offers the best results."

The authors' conclusion favouring embolization plus intralesional resection. Recorded as PARTIAL because the same abstract also concludes that en bloc resection should be preferred whenever possible, so this statement is a qualified recommendation for the sacral subset rather than a general one.

🔬

Diagnosis

Radiographic signature of giant cell tumor of bone

The lesion is diagnosed largely on its radiographic pattern in a specific clinical context: a purely lytic, geographically destructive lesion with circumscribed non-sclerotic borders, centred in the epiphysis but reaching the metaphysis and extending to the adjacent articular cortex, with no mineralized tumor matrix, in a patient with closed physes. Skeletal maturity is doing real diagnostic work here - it is the main clinical discriminator from chondroblastoma, which is also epiphyseal but occurs before physeal closure.

Imaging narrows the differential but does not close it. The definitive discriminator against giant-cell-rich mimics is H3.3 G34W mutant-protein immunohistochemistry or H3-3A sequencing, curated under histopathology.

Show evidence (3 references)

PMID:21139758 SUPPORT Other

"On radiographs, GCT demonstrates a lytic lesion centered in the epiphysis but involving the metaphysis and extending at least in part to the adjacent articular cortex."

States the defining radiographic location and extent. Evidence source is OTHER because this is a review article.

PMID:21139758 SUPPORT Other

"Most cases show circumscribed borders or so-called geographical destruction with no periosteal reaction unless a pathological fracture is present. There is no mineralized tumor matrix."

Gives the margin and matrix characteristics that separate this lesion from matrix-forming and permeative bone tumors. Evidence source is OTHER because this is a review article.

PMID:21139758 SUPPORT Other

"Giant cell tumor (GCT) of bone is a benign but locally aggressive and destructive lesion generally occurring in skeletally mature individuals."

Establishes skeletal maturity as part of the diagnostic context. Evidence source is OTHER because this is a review article.

📈

Progression

Local growth, treatment, and surveillance for recurrence

The usual course is a single episode of insidious local growth over months, surgical treatment, and then a surveillance period dominated by recurrence risk. Recurrence clusters early - median around 16 months - which sets the intensity of early follow-up, though the reported range extends to 15 years. Chest surveillance runs in parallel because pulmonary deposits appear later and are strongly associated with recurrence. Malignant transformation is a late and rare event.

Show evidence (2 references)

PMID:21301899 SUPPORT Human Clinical

"The median interval between initial surgery and the first recurrence of GCT was 16 months (2-180 months)."

Gives the timing and spread of first recurrence that shapes the surveillance schedule.

PMID:21301899 SUPPORT Human Clinical

"Early local recurrence of GCT is a risk factor for repeat recurrence."

Establishes that early recurrence predicts further recurrence, the basis for intensified follow-up after a first relapse.

🪜

Stages

Campanacci Grade I (latent)

A well-marginated intraosseous lesion with an intact cortex. Managed with extended intralesional curettage plus adjuvant; recurrence risk is lowest in this group.

early

Campanacci Grade II (active)

A relatively well-defined lesion without a radiopaque rim, with cortical thinning and moderate expansion. Still the domain of joint-preserving intralesional surgery.

intermediate

Campanacci Grade III (aggressive)

Ill-defined margins, cortical destruction, and soft-tissue extension. Grade III is the point at which the curettage-versus-resection calculation flips: intralesional treatment carries a markedly higher recurrence risk here, and grade III is independently a risk factor for pulmonary implantation. It is also the setting where neoadjuvant denosumab is used to downstage before surgery.

advanced

Campanacci grading is radiographic-surgical rather than an oncological stage; it describes local aggressiveness, not the benign/malignant distinction, which is captured separately by the Malignant Sarcomatous Transformation node.

Show evidence (3 references)

PMID:22773395 SUPPORT Human Clinical

"intralesional excision appears to be more appropriate for the treatment of local lesions (e.g., grades 1 and 2) than grade 3 GCTs of the distal radius"

Establishes grade III as the threshold at which intralesional treatment becomes the less appropriate option.

PMID:28443231 SUPPORT Human Clinical

"The Campanacci stage of all tumors was stage 3."

Every tumor in a 46-patient lung-metastasis series was Campanacci stage 3, supporting the association between this stage and pulmonary implantation.

PMID:20934816 SUPPORT Human Clinical

"Patients with a single site of cortical perforation who received CCC treatment achieved local control with intralesional treatment alone."

Qualifies the grade III rule: a subset with limited cortical perforation can still be managed intralesionally, so the grade is a guide rather than a hard boundary. Recorded as PARTIAL for that reason.

📊

Prevalence

Netherlands, nationwide pathology registry 2009-2013

Annual Incidence 0.17 per 100,000 <1 in 1,000,000

1.7 per million inhabitants per year, converted to 0.17 per 100,000. The first incidence estimate from a pathology database with complete national coverage, so it is less subject to the referral bias of doctor-driven registries.

Show evidence (1 reference)

PMID:29987945 SUPPORT Human Clinical

"For GCT-B the incidence was 1.7 per million inhabitants per year with a male to female ratio of 1:1.38 and a median age of 35 years (9-77)."

Provides the incidence rate, sex ratio, and age distribution recorded here.

United States, SEER 1975-2004, malignant giant cell tumor only

Annual Incidence 0.016 per 100,000 <1 in 1,000,000

1.6 per 10,000,000 per year for the malignant form specifically, roughly a tenth of the incidence of conventional GCTB. Do not compare this figure with the Dutch rate above as though they measured the same thing.

Show evidence (1 reference)

PMID:21139931 SUPPORT Human Clinical

"Based on analyses of 117 malignant GCT cases, the estimated annual incidence in the United States was 1.6 per 10,000,000 persons per year."

Population-based SEER incidence estimate for malignant giant cell tumor.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Bone Giant Cell Tumor:

Chondroblastoma

Overlapping Features The other epiphyseal giant-cell-rich bone tumor, and the sharpest mechanistic contrast in this entry: it is driven by a p.Lys36Met substitution in H3-3B rather than p.Gly34Trp in H3-3A. The two oncohistone lesions are mutually exclusive and tumor-type specific, so the molecular test separates them definitively. Clinically, chondroblastoma occurs before physeal closure, whereas GCTB occurs after.

Distinguishing Features

Driven by H3-3B p.Lys36Met rather than H3-3A p.Gly34Trp
Occurs in the skeletally immature, before physeal closure
Negative for H3.3 G34W mutant-protein immunohistochemistry

Show evidence (2 references)

PMID:24162739 SUPPORT Human Clinical

"In 73 of 77 cases of chondroblastoma (95%), we found p.Lys36Met alterations predominantly encoded in H3F3B, which is one of two genes for histone H3.3."

Establishes the distinct driver alteration and gene that separate chondroblastoma from GCTB.

PMID:33021329 SUPPORT Human Clinical

"Other bone tumors all showed wild-type expression in both DNA sequencing and immunohistochemistry."

Confirms that the non-GCTB tumors in the series, chondroblastoma among them, were negative by both assays.

Tenosynovial Giant Cell Tumor

Overlapping Features Shares the words "giant cell tumor" and nothing mechanistic. TGCT arises from joints, bursae, and tendon sheaths rather than bone, and is driven by CSF1 rather than an oncohistone - so its targeted therapy is CSF1R inhibition, not RANKL blockade. Conflating the two is a real risk when searching the literature by name.

Distinguishing Features

Arises from synovium, bursa, or tendon sheath rather than within bone
CSF1-driven, treated with CSF1R inhibitors rather than anti-RANKL antibody
Not associated with H3-3A p.Gly34Trp

Show evidence (2 references)

PMID:36502615 SUPPORT Other

"Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths."

Establishes the distinct anatomical origin that separates TGCT from a primary bone tumor. Evidence source is OTHER because this is a consensus paper.

PMID:36502615 SUPPORT Other

"CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries."

Documents the entirely different drug target, the practical consequence of confusing the two entities. Evidence source is OTHER because this is a consensus paper.

Aneurysmal Bone Cyst

Overlapping Features A blood-filled cystic lytic lesion that both mimics GCTB radiographically and occurs as a secondary change within one. Fluid-fluid levels on MRI favour it, but their presence does not exclude a giant cell tumor with secondary cystic change - which is why the H3.3 G34W stain matters here.

Distinguishing Features

Fluid-fluid levels on MRI, though these also occur in GCTB with secondary cystic change
Negative for H3.3 G34W mutant-protein immunohistochemistry

Show evidence (1 reference)

PMID:33021329 SUPPORT Human Clinical

"Other bone tumors all showed wild-type expression in both DNA sequencing and immunohistochemistry."

The nine aneurysmal bone cysts in this series were among the non-GCTB tumors negative by both assays, supporting the molecular discriminator.

Malignant Giant Cell Tumor of Bone

Overlapping Features Not a mimic but a progression, and the distinction that changes management most. A high-grade sarcoma arising primarily alongside or secondarily at the site of a conventional tumor. It may retain or lose the H3.3 G34W stain, so a negative stain in a giant-cell-rich sarcoma does not exclude it.

Distinguishing Features

High-grade sarcomatous histology, most often osteosarcoma
May carry TP53 mutation or loss of H3K27me3
The H3-3A G34W mutation is lost in a substantial fraction of malignant components

Show evidence (1 reference)

PMID:31285528 SUPPORT Human Clinical

Documents the mutation loss that makes a negative stain uninformative for excluding malignant transformation.

📊

Related Datasets

Single-cell RNA sequencing of human giant cell tumor of bone geo:GSE168664

human SINGLE CELL RNA SEQ n=1

Single-cell resolution of the tripartite GCTB ecosystem. Relevant because the disease's central claim is about cross-talk between compartments that bulk profiling cannot separate. Triaged as directly on-disease: the series title names giant cell tumor of bone and the material is human tumor.

Single cell sequencing reveals the immunosuppressive trajectory in the tumor microenvironment of human giant cell tumor geo:GSE254672

human SINGLE CELL RNA SEQ n=1

Microenvironment-focused single-cell data. Triaged as directly on-disease from the series title.

RNA-Seq analysis for giant cell tumour of the bone geo:GSE206448

human BULK RNA SEQ n=10

Bulk transcriptomes of human giant cell tumor of bone.

Gene expression profile of human osteoclastoma bone tumor derived giant osteoclast cells geo:GSE148616

human MICROARRAY n=2

Profiles the giant osteoclast compartment specifically, which is the reactive rather than neoplastic population - the one distinction this entry turns on. Small (n=2), so it is a resource pointer rather than a basis for quantitative claims. "Osteoclastoma" is the historical synonym for this disease, not a different entity.

🔬

Clinical Trials

NCT00680992 PHASE_II COMPLETED

The pivotal open-label multicentre phase 2 study of denosumab in GCTB, 532 patients across 30 sites in 12 countries, which established the safety profile and long-term disease control underpinning approval. Its published results are curated as PMID:31704134.

Target Phenotypes: Giant cell tumor of bone HP:0011847

Show evidence (1 reference)

clinicaltrials:NCT00680992 SUPPORT Human Clinical

"To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)"

States the trial's objective, confirming it as the denosumab safety study in this disease.

NCT00889590 PHASE_II UNKNOWN

Randomised phase 2 trial of adjuvant zoledronic acid in high-risk GCTB, testing whether systemic bisphosphonate lowers the 2-year recurrence rate against standard care. Directly tests the anti-stromal rationale curated on the zoledronic acid treatment entry.

Target Phenotypes: Giant cell tumor of bone HP:0011847

Show evidence (1 reference)

clinicaltrials:NCT00889590 SUPPORT Human Clinical

"Determine if adjuvant zoledronic acid improves the 2 years recurrence rate of 'high risk' GCT as compared to standard care"

States the primary objective, the recurrence endpoint this entry's recurrence node is concerned with.

NCT05595603 NOT_APPLICABLE UNKNOWN

Randomised trial of zoledronic-acid-loaded bone cement as a local adjuvant after intralesional curettage. The local-delivery design is the direct response to the recurrence problem curated at the curettage treatment entry: it aims at the residual mutant stroma in the cavity wall while avoiding systemic bisphosphonate exposure.

Target Phenotypes: Giant cell tumor of bone HP:0011847

Show evidence (1 reference)

clinicaltrials:NCT05595603 SUPPORT Human Clinical

"The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery."

States the intervention and the local-recurrence endpoint.

🧫

Experimental Models

Patient-derived GCTB stromal cell culture PRIMARY_CELL_CULTURE

Primary mononuclear stromal cells outgrown from surgical GCTB specimens, carrying the endogenous H3.3-G34W mutation at physiological expression levels. This is the workhorse system of the field: essentially all mechanistic knowledge of the oncohistone's chromatin effects, the osteogenic differentiation block, and the SCUBE3/SEMA4D paracrine axis derives from it.

Organism

human NCBITaxon:9606

Cell source

Surgical giant cell tumor of bone specimens

Publication

PMID:33110075

Pathograph links

Genome-Wide Epigenetic Reprogramming by Mutant Histone H3.3 recapitulates fidelity: high Reproduces the chromatin incorporation of mutant H3.3 and the genome-wide DNA methylation, accessibility, and histone-mark changes in cells carrying the endogenous mutation.

Limitations: Cultured stromal cells are isolated from the osteoclast compartment and bone matrix that shape their behaviour in vivo, so the paracrine loop curated in this entry cannot operate in monoculture. Outgrowth also selects for proliferative cells, and the differentiation stage of the cultured population is itself a confounder the source study raises.

Readouts

Genome-wide DNA methylation, chromatin accessibility, and histone modification profiles

Direction: ALTERED

Interpretation: Multi-layer epigenomic profiling is the measurement that grounds this node.

Show evidence (1 reference)

PMID:33110075 SUPPORT In Vitro

Names the three measurement layers reported for this readout.

Show evidence (1 reference)

PMID:33110075 SUPPORT In Vitro

"These epigenetic alterations affect mainly heterochromatic and bivalent regions and provide possible explanations for the genomic instability, as well as the osteolytic phenotype of GCTB."

Reports what the model shows about this node and how the authors connect it to the disease phenotype.

Arrested Osteogenic Differentiation of the Neoplastic Stroma recapitulates fidelity: high Mutant patient-derived cells show impaired osteogenic differentiation under differentiation conditions.

Limitations: Differentiation assays are driven by supraphysiological osteogenic media rather than the in vivo niche, and the source study frames the finding as a delay in differentiation stage, which is a weaker claim than a permanent block.

Readouts

Osteogenic differentiation capacity of mutant versus wild-type stromal cells

Direction: DECREASED

Interpretation: Reduced osteogenic differentiation is the direct cellular correlate of the differentiation-block node.

Show evidence (1 reference)

PMID:33110075 SUPPORT In Vitro

"The mutation occurs in differentiating mesenchymal stem cells and associates with an impaired osteogenic differentiation."

Reports the measured impairment of osteogenic differentiation.

Show evidence (1 reference)

PMID:33110075 SUPPORT In Vitro

"We propose that the observed epigenetic alterations reflect distinct differentiation stages of H3.3 WT and H3.3 MUT stromal cells"

The authors' own framing of what the model shows, preserved with its hedging. Recorded as PARTIAL because it qualifies the differentiation claim rather than simply confirming it.

Show evidence (1 reference)

PMID:33110075 SUPPORT In Vitro

"The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration."

Establishes that cells cultured from GCTB specimens carry the disease-defining lesion, which is what makes this culture system a valid model of the human disease.

CRISPR-Cas9 H3.3 G34W-edited GCTB tumor-derived cells CELL_LINE

Tumor-derived cells in which the G34W allele is introduced or removed by genome editing. This is what converts the mutation from a correlate into a demonstrated requirement, and it is the only system in which necessity for tumor formation has been tested.

Organism

human NCBITaxon:9606

Cell source

GCTB tumor-derived cells edited for H3.3 G34W

Publication

PMID:32967858

Pathograph links

Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells perturbs fidelity: high Directly manipulates the driver allele, establishing that G34W is necessary for tumor formation rather than merely associated with it.

Limitations: Editing is performed in established tumor-derived cells that already carry the tumor's other acquired changes, so the experiment tests the mutation's requirement for maintaining the transformed state more directly than its sufficiency to initiate one in a normal mesenchymal progenitor.

Readouts

Tumor formation by G34W-edited versus unedited cells

Direction: ABOLISHED

Interpretation: Loss of tumor formation on removing the allele is the necessity test.

Show evidence (1 reference)

PMID:32967858 SUPPORT In Vitro

"Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3 G34W is necessary for tumor formation."

States the necessity result this readout records.

Show evidence (1 reference)

PMID:32967858 SUPPORT In Vitro

"Our findings suggest that H3.3 G34W leads to GCT by sustaining a transformed state in osteoblast-like progenitors, which promotes neoplastic growth, pathologic recruitment of giant osteoclasts, and bone destruction."

The authors' summary of what perturbing the allele in this system establishes about the driver node.

Show evidence (1 reference)

PMID:32967858 SUPPORT In Vitro

"By profiling the epigenome, transcriptome, and secreted proteome of patient samples and tumor-derived cells CRISPR-Cas9-edited for H3.3 G34W"

Describes the edited tumor-derived system and the multi-omic profiling that establish it as a model of the driver mutation.

Monocyte osteoclastogenesis co-culture with GCTB stromal cells CO_CULTURE

Peripheral monocytes cultured with GCTB stromal cells or their secreted factors, reading out multinucleated osteoclast formation. This is the system in which the paracrine arm of the disease is actually measured - including the recombinant-SCUBE3 add-back that tests the de-repression mechanism directly - and it is the one place the two compartments are reconstituted together.

Organism

human NCBITaxon:9606

Cell source

Human peripheral blood monocytes with GCTB stromal cells

Publication

PMID:36138226

Pathograph links

Enhancer-Level SCUBE3 Repression measures fidelity: moderate Quantifies osteoclast formation as a function of stromal SCUBE3, the readout that establishes SCUBE3 as a restraint rather than a bystander.

Limitations: An in vitro reconstitution of two purified compartments cannot reproduce the bone matrix, vasculature, or the recruitment step that precedes fusion in vivo; osteoclast number and size in a dish are a proxy for tumor osteolysis, not a measurement of it.

Readouts

Osteoclast number and size generated from monocyte precursors

Direction: INCREASED

Interpretation: Osteoclast output rises as stromal SCUBE3 falls, the direction the de-repression model predicts.

Show evidence (1 reference)

PMID:36138226 SUPPORT In Vitro

Reports the measured increase in osteoclast recruitment attributable to reduced SCUBE3.

Show evidence (1 reference)

PMID:34556636 SUPPORT In Vitro

"Stromal-derived SRGN promotes osteoclast differentiation from monocytes."

An independent use of the same co-culture readout, supporting it as the established assay for the stromal-to-osteoclast axis.

Show evidence (1 reference)

PMID:36138226 SUPPORT In Vitro

"While these striking features imply a pathogenic interaction between mesenchymal and myelomonocytic lineages during GCT development, the underlying mechanisms remain unknown."

States the two-compartment interaction this co-culture system exists to reconstitute and measure.

🐁

Animal Models

Naturally occurring canine vertebral giant cell tumor of bone

A spontaneous primary lumbar extradural giant cell tumor in a 10-year-old Poodle, characterized by imaging, necropsy, histology, histochemistry, and immunohistochemistry. It reproduces the human tumor's cellular architecture - TRAP-positive osteoclastic giant cells evenly distributed among alpha-SMA-positive spindled mononuclear cells and IBA-1-positive histiocytic cells - and its destructive osteolysis. It is the only naturally occurring non-human example identified in this curation pass, and it is included for what it fails to show as much as for what it shows.

Species

Dog

Genotype

Not determined; spontaneous tumor in a wild-type animal

Publication

PMID:41908959

Pathograph links

Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells recapitulates fidelity: moderate The canine tumor contains the same tripartite cellular composition as the human disease, with abundant osteoclast-type multinucleated giant cells distributed among mononuclear stromal and histiocytic populations.

Limitations: A single spontaneous case, characterized only at necropsy. Fidelity is capped at MODERATE rather than HIGH because the compositional match is morphological and immunophenotypic; no genotyping was performed, so the canine giant cells are not shown to be reactive to a mutant stromal population in the way that defines the human mechanism.

Readouts

TRAP-positive multinucleated giant cells distributed among mononuclear cells

Direction: INCREASED

Interpretation: Histochemical confirmation of an osteoclast-type giant cell population in the canine tumor.

Show evidence (1 reference)

PMID:41908959 SUPPORT Model Organism

"The tumor comprised numerous multinucleated giant cells of the osteoclastic type (positive for tartrate-resistant acid phosphatase- TRAP- and lysozyme), evenly distributed among mononuclear cells (both rounded and spindle-shaped)."

Reports the TRAP-positive giant cell population and its even distribution among mononuclear cells.

Show evidence (1 reference)

PMID:41908959 SUPPORT Model Organism

"Alpha smooth muscle actin (SMA) was expressed in mononuclear cells, while IBA-1 staining highlighted mononuclear histiocytic cells."

Documents the two mononuclear populations alongside the giant cells, establishing the compositional match that makes this animal informative for the node.

Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells fails to recapitulate fidelity: low Immunohistochemistry with the H3.3 G34W mutation-specific antibody showed no nuclear reactivity in the canine tumor. The animal reproduces the disease's cellular architecture without demonstrating the molecular driver that defines it in humans, so it cannot serve as a model of the oncohistone mechanism curated at this node.

Limitations: The negative result is not decisive about canine biology. The antibody is validated for human tissue only, so a species difference in the H3.3 sequence context or simple loss of cross-reactivity would produce the same absent stain as a genuinely different driver. No sequencing was performed, and this is a single case. The honest reading is that the driver is undetermined in the dog, not that it is absent - which is precisely why the link is FAILS_TO_RECAPITULATE at LOW fidelity rather than a species-divergence claim.

Show evidence (1 reference)

PMID:41908959 SUPPORT Model Organism

"Both masses exhibited whitish areas interspersed with blood-filled spaces."

Establishes from the abstract that this is the canine tumor in question. Recorded as PARTIAL because the abstract does not itself report the G34W immunohistochemistry; that result appears in the report body, and the failure-to-recapitulate claim rests on it rather than on this quote.

The G34W-negative immunohistochemistry is stated in the case report's results and discussion rather than its abstract, so it is not quoted as a snippet here - abstract-only reference validation would not verify it. The open question it raises is curated as a HUMAN_MODEL_MISMATCH discussion.

Show evidence (1 reference)

PMID:41908959 SUPPORT Model Organism

"The final diagnosis was a primary lumbar extradural giant cell tumor of bone."

Confirms the diagnosis in the animal, the basis for treating this spontaneous case as informative about the human disease.

{ }

Source YAML

click to show

name: Bone Giant Cell Tumor
description: >-
  Giant cell tumor of bone (GCTB, historically "osteoclastoma") is a locally
  aggressive, rarely metastasizing primary bone neoplasm that arises in the
  epiphyseal-metaphyseal region of long bones in skeletally mature young
  adults. It is defined by a somatic H3-3A (H3F3A) p.Gly34Trp oncohistone
  mutation confined to a neoplastic mesenchymal stromal cell population, which
  is arrested in osteoblastic differentiation and drives paracrine recruitment
  of a large, non-neoplastic osteoclast compartment. The multinucleated
  osteoclast-like giant cells that give the tumor its name are therefore
  reactive rather than neoplastic, and their RANKL-driven resorptive activity
  produces the defining geographic osteolysis. The disease is the clearest
  human example of a neoplasm whose destructive phenotype is executed almost
  entirely by a recruited bystander cell type - the mechanistic basis for
  treating it with the anti-RANKL antibody denosumab, and for the tumor's
  regrowth when that drug is withdrawn while the mutant stroma persists.
creation_date: "2026-08-15T23:45:00Z"
disease_term:
  preferred_term: bone giant cell tumor
  term:
    id: MONDO:0005674
    label: bone giant cell tumor
synonyms:
- Giant cell tumor of bone
- GCTB
- Osteoclastoma
- Benign bone giant cell tumor
notes: >-
  Scoped to conventional sporadic GCTB, which is modeled as a somatic-driver
  neoplasm: no germline predisposition allele is established for it, so no
  `inheritance:` block is asserted. HPO's "Somatic mutation" term (HP:0001428)
  is obsolete and is deliberately not used.


  That "no inheritance" claim is deliberately narrow and does not extend to the
  whole disease name. A distinct familial/multicentric subset arises in Paget
  disease of bone, with strong familial clustering, flat-bone predilection, and
  a far worse prognosis; it is curated here as an out-of-scope KNOWLEDGE_GAP
  discussion (`gctb_paget_associated_familial_subset`) rather than folded into
  this entry, because its predisposition is most plausibly inherited through
  Paget disease genetics rather than through anything in the GCTB mechanism
  graph, and the retrieved literature does not establish the germline basis of
  the GCT phenotype specifically. A separate entry for PDB-associated GCT would
  be the right home for it.


  Distinguish carefully from two same-named but mechanistically distinct
  entities: tenosynovial giant cell tumor (CSF1-driven, of joints and tendon
  sheaths) and giant cell tumor of soft tissue. Chondroblastoma is the
  epiphyseal H3-3B/H3F3B p.Lys36Met counterpart and is a separate disease.
classifications:
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:31704134
      reference_title: 'Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Giant-cell tumour of bone (GCTB) is a rare, locally aggressive
        osteoclastogenic stromal tumour of the bone.
      explanation: >-
        Characterizes GCTB as a bone tumor managed in the oncology setting,
        supporting the oncology classification.

pathophysiology:
- name: Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells
  description: >-
    The initiating and, in conventional GCTB, essentially the only recurrent
    genetic lesion is a somatic missense mutation at codon 34 of histone H3.3,
    canonically H3-3A (H3F3A) c.103G>T p.Gly34Trp. Critically for everything
    downstream, the mutation is confined to the mononuclear mesenchymal stromal
    cell population and is absent from the osteoclast-like giant cells and
    their myelomonocytic precursors: the cells that give the tumor its name are
    not the tumor. Rarer substitutions at the same codon (G34L, G34V, G34R)
    account for a small remainder of cases.
  biological_scale: MOLECULAR
  role: trigger
  cell_types:
  - preferred_term: Neoplastic mesenchymal stromal cell
    term:
      id: CL:0000134
      label: mesenchymal stem cell
  evidence:
  - reference: PMID:24162739
    reference_title: Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in 92% (49/53) of giant cell tumors of bone, we found histone H3.3
      alterations exclusively in H3F3A, leading to p.Gly34Trp or, in one case,
      p.Gly34Leu alterations
    explanation: >-
      Establishes the H3F3A G34 substitution, predominantly G34W, as the
      near-universal recurrent driver of GCTB.
  - reference: PMID:24162739
    reference_title: Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mutations were restricted to the stromal cell population and were not
      detected in osteoclasts or their precursors.
    explanation: >-
      Directly localizes the driver mutation to the stromal compartment and
      excludes the giant cells, which is the mechanistic premise of every
      downstream node in this entry.
  - reference: PMID:32967858
    reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in
      approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3
      G34W is necessary for tumor formation.
    explanation: >-
      CRISPR-Cas9 editing of patient-derived cells establishes that G34W is not
      merely a marker but is required for tumor formation.
  - reference: PMID:33021329
    reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DNA sequencing results revealed H3F3A mutations in 95.00% of GCTBs
      (171/180), including glycine 34 to tryptophan (G34W, 163/180, 90.56%),
      glycine 34 to leucine (G34L, 3/180, 1.67%), glycine 34 to valine (G34V,
      3/180, 1.67%), and glycine 34 to arginine (G34R, 2/180, 1.11%).
    explanation: >-
      Quantifies the mutational spectrum at codon 34 in a large sequenced
      series, supporting G34W dominance and the rarer alternative substitutions.
  downstream:
  - target: Genome-Wide Epigenetic Reprogramming by Mutant Histone H3.3
    causal_link_type: DIRECT
    description: >-
      Mutant H3.3 is incorporated into chromatin and perturbs the histone-mark
      landscape from within the nucleosome.
    evidence:
    - reference: PMID:33110075
      reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: in patient-derived stromal cells H3.3-G34W is incorporated into the chromatin and associates with massive epigenetic alterations on the DNA methylation, chromatin accessibility and histone modification level
      explanation: Shows chromatin incorporation of the mutant histone producing the genome-wide epigenetic change this edge asserts.

- name: Genome-Wide Epigenetic Reprogramming by Mutant Histone H3.3
  description: >-
    Incorporated H3.3-G34W acts in cis on its own tail - the bulky tryptophan at
    position 34 impairs H3K36 trimethylation of the mutant histone - and the
    consequences propagate genome-wide. The repressive H3K27me3 mark is
    redistributed from intergenic to genic regions, and DNA methylation,
    chromatin accessibility, and other histone modifications shift with it,
    most markedly over heterochromatic and bivalent domains. The result is
    aberrant transcription across a broad program rather than dysregulation of
    a single target gene.
  biological_scale: MOLECULAR
  role: mediator
  biological_processes:
  - preferred_term: Chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: ABNORMAL
  - preferred_term: Heterochromatin organization
    term:
      id: GO:0070828
      label: heterochromatin organization
    modifier: ABNORMAL
  evidence:
  - reference: PMID:32967858
    reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we show that H3.3K36me3 loss on mutant H3.3 alters the deposition of the
      repressive H3K27me3 mark from intergenic to genic regions, beyond areas of
      H3.3 deposition
    explanation: >-
      States the specific chromatin-mark redistribution that defines this node,
      including its spread beyond sites of mutant H3.3 deposition.
  - reference: PMID:33110075
    reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      in patient-derived stromal cells H3.3-G34W is incorporated into the
      chromatin and associates with massive epigenetic alterations on the DNA
      methylation, chromatin accessibility and histone modification level
    explanation: >-
      Independently confirms genome-wide, multi-layer epigenetic disruption in
      patient-derived stromal cells.
  - reference: PMID:33110075
    reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These epigenetic alterations affect mainly heterochromatic and bivalent
      regions and provide possible explanations for the genomic instability, as
      well as the osteolytic phenotype of GCTB.
    explanation: >-
      Localizes the changes to heterochromatic and bivalent domains and links
      them to the osteolytic phenotype curated downstream.
  downstream:
  - target: Arrested Osteogenic Differentiation of the Neoplastic Stroma
    causal_link_type: DIRECT
    description: >-
      Aberrant transcription redirects mesenchymal cell fate away from mature
      osteoblastic differentiation.
    evidence:
    - reference: PMID:32967858
      reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: This promotes redistribution of other chromatin marks and aberrant transcription, altering cell fate in mesenchymal progenitors and hindering differentiation.
      explanation: States the causal step from chromatin-mark redistribution to altered mesenchymal cell fate and impaired differentiation.
  - target: Enhancer-Level SCUBE3 Repression
    causal_link_type: DIRECT
    description: >-
      Mutant-H3.3 enrichment and altered histone marks at SCUBE3 enhancers
      silence a paracrine restraint on osteoclast recruitment.
    evidence:
    - reference: PMID:36138226
      reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Transcriptional changes in SCUBE3 are associated with altered histone marks and H3.3G34W enrichment at its enhancer regions.
      explanation: Links the altered histone marks to SCUBE3 transcriptional repression, the specific edge curated here.

- name: Arrested Osteogenic Differentiation of the Neoplastic Stroma
  description: >-
    The mutation arises in a differentiating mesenchymal stem cell and holds it
    short of mature osteoblast identity. Mutant stromal cells retain
    proliferative capacity while failing to complete osteogenic differentiation,
    tracing a neoplastic trajectory from an SPP1-positive osteoblast-like
    progenitor state toward an ACTA2-positive myofibroblast-like state that
    secretes the matrix ligands recruiting osteoclasts. This is the neoplastic
    compartment of the tumor, and it is histologically the least conspicuous.
  biological_scale: CELLULAR
  role: mediator
  cell_types:
  - preferred_term: Osteoblast-like mesenchymal progenitor
    term:
      id: CL:0000134
      label: mesenchymal stem cell
  biological_processes:
  - preferred_term: Osteoblast differentiation
    term:
      id: GO:0001649
      label: osteoblast differentiation
    modifier: DECREASED
  - preferred_term: Stromal cell proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
    modifier: INCREASED
  evidence:
  - reference: PMID:33110075
    reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The mutation occurs in differentiating mesenchymal stem cells and
      associates with an impaired osteogenic differentiation.
    explanation: >-
      Identifies the cell of origin as a differentiating mesenchymal stem cell
      and the differentiation block that defines this node.
  - reference: PMID:32967858
    reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      This promotes redistribution of other chromatin marks and aberrant
      transcription, altering cell fate in mesenchymal progenitors and hindering
      differentiation.
    explanation: >-
      Connects the upstream epigenetic node to the altered mesenchymal cell fate
      and differentiation block curated here.
  - reference: PMID:32967858
    reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Single-cell transcriptomics reveals that H3.3 G34W stromal cells
      recapitulate a neoplastic trajectory from a SPP1+ osteoblast-like
      progenitor population toward an ACTA2+ myofibroblast-like population,
      which secretes extracellular matrix ligands predicted to recruit and
      activate osteoclasts.
    explanation: >-
      Provides the single-cell resolved identity of the neoplastic stromal
      compartment and its link to osteoclast recruitment.
  - reference: PMID:22662295
    reference_title: 'Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The modern interpretation of GCT is predominantly osteoclastogenic stromal
      cell tumors of mesenchymal origin.
    explanation: >-
      Review framing that the neoplastic compartment is the mesenchymal stromal
      cell, not the giant cell. Evidence source is OTHER because this is a
      review article.
  downstream:
  - target: Stromal RANKL Overexpression
    causal_link_type: DIRECT
    description: >-
      The arrested, transformed stroma expresses RANKL and monocyte-recruiting
      chemokines at levels that drive osteoclastogenesis.
    evidence:
    - reference: PMID:29944971
      reference_title: 'Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: mononuclear stromal cells in GCTB express fundamental RANKLs and various chemokines and cytokines associated with monocyte recruitment
      explanation: Places RANKL and monocyte-recruiting signal output in the neoplastic stromal compartment. Evidence source is OTHER because this is a review article.
  - target: Malignant Sarcomatous Transformation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A small minority of these neoplastic stromal populations acquire
      additional TP53 or telomerase alterations and progress to a high-grade
      sarcoma.
    evidence:
    - reference: PMID:34785767
      reference_title: 'Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The results suggested that p53 alteration and dysfunction of histone methylation as evidenced by H3K27me3 loss may play an important role in the malignant progression of GCTB
      explanation: Supports progression of the neoplastic compartment to malignancy through additional acquired alterations, with the authors' hedging preserved - which is why the target node carries mechanism_confidence PROVISIONAL.

- name: Enhancer-Level SCUBE3 Repression
  description: >-
    Among the transcriptional consequences of the oncohistone, one has been
    resolved to a specific paracrine mediator. Mutant H3.3 is enriched at the
    enhancer regions of SCUBE3, which encodes a secreted TGF-beta-like factor,
    and the accompanying histone-mark changes reduce its expression. Loss of
    stromal SCUBE3 removes a brake on osteoclast recruitment, so this node is a
    de-repression step rather than an activating one - the tumor recruits
    osteoclasts partly by ceasing to restrain them.
  biological_scale: MOLECULAR
  role: mediator
  biological_processes:
  - preferred_term: Positive regulation of osteoclast differentiation
    term:
      id: GO:0045672
      label: positive regulation of osteoclast differentiation
    modifier: INCREASED
  evidence:
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We show that the changes in the transcriptome and epigenome in the
      mesenchymal cells caused by the H3.3-G34W mutation contribute to increase
      osteoclast recruitment in part via reduced expression of the TGFβ-like
      soluble factor, SCUBE3.
    explanation: >-
      States the causal chain from the oncohistone through reduced SCUBE3 to
      increased osteoclast recruitment that this node represents.
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Transcriptional changes in SCUBE3 are associated with altered histone
      marks and H3.3G34W enrichment at its enhancer regions.
    explanation: >-
      Provides the enhancer-level chromatin mechanism linking mutant H3.3
      occupancy to SCUBE3 repression.
  downstream:
  - target: Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells
    causal_link_type: DIRECT
    description: >-
      Loss of the SCUBE3 restraint permits greater osteoclast recruitment to the
      tumor site.
    evidence:
    - reference: PMID:36138226
      reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We show that the changes in the transcriptome and epigenome in the mesenchymal cells caused by the H3.3-G34W mutation contribute to increase osteoclast recruitment in part via reduced expression of the TGFβ-like soluble factor, SCUBE3.
      explanation: Attributes increased osteoclast recruitment specifically to reduced SCUBE3, the edge asserted here.

- name: Stromal RANKL Overexpression
  description: >-
    The neoplastic stromal cells express RANKL (TNFSF11), the master
    differentiation and survival signal for the osteoclast lineage, alongside
    monocyte-recruiting chemokines such as SDF-1 and MCP-1 and pro-osteoclastic
    cytokines including IL-6 and TNF. RANKL engages RANK on myelomonocytic
    precursors that the tumor has recruited. This is the therapeutically
    actionable step: it is the node that denosumab occupies.
  biological_scale: MOLECULAR
  role: amplifier
  conforms_to: "osteoporosis_bone_resorption#RANKL-Driven Osteoclastogenesis"
  cell_types:
  - preferred_term: Neoplastic mesenchymal stromal cell
    term:
      id: CL:0000134
      label: mesenchymal stem cell
  biological_processes:
  - preferred_term: Osteoclast differentiation
    term:
      id: GO:0030316
      label: osteoclast differentiation
    modifier: INCREASED
  evidence:
  - reference: PMID:20149736
    reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GCT is rich in osteoclast-like giant cells and contains mononuclear
      (stromal) cells that express RANK ligand (RANKL), a key mediator of
      osteoclast activation.
    explanation: >-
      Attributes RANKL expression specifically to the mononuclear stromal cells
      and names it the key mediator of osteoclast activation.
  - reference: PMID:29944971
    reference_title: 'Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      mononuclear stromal cells in GCTB express fundamental RANKLs and various
      chemokines and cytokines associated with monocyte recruitment
    explanation: >-
      Confirms that the stromal compartment supplies both RANKL and the
      monocyte-recruiting signals feeding the osteoclast pool. Evidence source
      is OTHER because this is a review article.
  - reference: PMID:22662295
    reference_title: 'Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Pro-osteoclastogenic cytokines such as receptor activator of nuclear
      factor kappa-B ligand (RANKL), interleukin (IL)-6, and tumor necrosis
      factor (TNF) as well as monocyte-recruiting chemokines such as stromal
      cell-derived factor-1 (SDF-1) and monocyte chemoattractant protein (MCP)-1
      participate in unfavorable osteoclastogenesis and bone destruction.
    explanation: >-
      Enumerates the wider cytokine and chemokine program accompanying RANKL in
      driving osteoclastogenesis and bone destruction. Evidence source is OTHER
      because this is a review article.
  downstream:
  - target: Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells
    causal_link_type: DIRECT
    description: >-
      RANKL-RANK engagement drives differentiation and fusion of recruited
      monocytic precursors into multinucleated osteoclasts.
    evidence:
    - reference: PMID:20149736
      reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: GCT is rich in osteoclast-like giant cells and contains mononuclear (stromal) cells that express RANK ligand (RANKL), a key mediator of osteoclast activation.
      explanation: Names stromal RANKL as the key mediator of osteoclast activation, the causal step this edge encodes.

- name: Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells
  description: >-
    Monocyte-macrophage lineage precursors recruited into the lesion
    differentiate and fuse into the enormous multinucleated osteoclast-like
    giant cells, frequently carrying more than fifty nuclei, that dominate the
    tumor histologically and supply its name. These cells carry no driver
    mutation: they are a reactive population induced by the neoplastic stroma.
    Additional stromal products, including the proteoglycan serglycin, promote
    the same differentiation step.
  biological_scale: CELLULAR
  role: effector
  cell_types:
  - preferred_term: Osteoclast-like multinucleated giant cell
    term:
      id: CL:0000092
      label: osteoclast
  - preferred_term: Recruited monocytic precursor
    term:
      id: CL:0000576
      label: monocyte
  biological_processes:
  - preferred_term: Syncytium formation by cell-cell fusion
    term:
      id: GO:0000768
      label: syncytium formation by cell-cell fusion
    modifier: INCREASED
  evidence:
  - reference: PMID:34556636
    reference_title: Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Giant cell tumor of bone (GCTB) is an aggressive osteolytic bone tumor
      characterized by the within-tumor presence of osteoclast-like
      multinucleated giant cells (MGCs), which are induced by the neoplastic
      stromal cells and lead to extensive bone destruction.
    explanation: >-
      States that the giant cells are induced by the neoplastic stroma and that
      they are the proximate cause of bone destruction.
  - reference: PMID:34556636
    reference_title: Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Stromal-derived SRGN promotes osteoclast differentiation from monocytes."
    explanation: >-
      Identifies serglycin as an additional stromal factor driving the
      monocyte-to-osteoclast transition curated at this node.
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Giant cell tumours of bone (GCTs) are characterised by a mutated histone
      H3.3 as the sole genetic driver present in bone-forming osteoprogenitor
      cells but absent from abnormally large bone-resorbing osteoclasts which
      represent the hallmark of these neoplasms.
    explanation: >-
      Confirms that the hallmark giant cells lack the driver mutation and are
      therefore reactive rather than neoplastic.
  downstream:
  - target: Excessive Osteoclastic Bone Resorption
    causal_link_type: DIRECT
    description: >-
      The expanded osteoclast pool resorbs mineralized matrix far in excess of
      replacement.
    evidence:
    - reference: PMID:34556636
      reference_title: Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: osteoclast-like multinucleated giant cells (MGCs), which are induced by the neoplastic stromal cells and lead to extensive bone destruction
      explanation: States that the induced giant cells are what produce extensive bone destruction.
  - target: Osteoclast-Derived SEMA4D Feedback onto the Mutant Stroma
    causal_link_type: DIRECT
    description: >-
      Activated osteoclasts secrete SEMA4D, closing a paracrine loop back onto
      the neoplastic compartment.
    evidence:
    - reference: PMID:36138226
      reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances proliferation of mutated osteoprogenitors arresting their maturation.
      explanation: Documents osteoclast-derived SEMA4D secretion, the origin of the feedback arm.

- name: Osteoclast-Derived SEMA4D Feedback onto the Mutant Stroma
  description: >-
    The stroma-to-osteoclast axis is not one-way. Osteoclasts in GCTB secrete
    unregulated amounts of SEMA4D, which enhances proliferation of the mutant
    osteoprogenitors while arresting their maturation - reinforcing the very
    differentiation block that generated the osteoclast pool. The loop makes
    the neoplastic stroma partly dependent on the reactive compartment it
    creates, and this dependency is what makes depleting osteoclasts a
    therapeutically meaningful intervention rather than a purely symptomatic one.
  biological_scale: MOLECULAR
  role: amplifier
  cell_types:
  - preferred_term: Osteoclast-like multinucleated giant cell
    term:
      id: CL:0000092
      label: osteoclast
  evidence:
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances
      proliferation of mutated osteoprogenitors arresting their maturation.
    explanation: >-
      States the reverse arm of the paracrine loop, both the proliferative
      effect and the maturation arrest, exactly as curated here.
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These findings provide a mechanism by which GCTs undergo differentiation
      in response to denosumab, a drug that depletes the tumour of osteoclasts.
    explanation: >-
      Links the feedback loop to the observed stromal differentiation seen when
      osteoclasts are depleted by denosumab, supporting the loop's therapeutic
      relevance.
  downstream:
  - target: Arrested Osteogenic Differentiation of the Neoplastic Stroma
    causal_link_type: DIRECT
    description: >-
      SEMA4D feeds back onto the neoplastic stroma, sustaining proliferation and
      the maturation block. This is a deliberate feed-forward cycle in the
      pathograph, not a curation error.
    evidence:
    - reference: PMID:36138226
      reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances proliferation of mutated osteoprogenitors arresting their maturation.
      explanation: 'The same sentence supplies the return arm: SEMA4D acting on the mutant osteoprogenitors to sustain proliferation and maturation arrest.'

- name: Excessive Osteoclastic Bone Resorption
  description: >-
    The recruited osteoclast pool degrades mineralized matrix at a rate the
    arrested, non-differentiating stroma cannot replace with new bone. Because
    the stroma is held short of mature osteoblast identity, the formative arm
    of remodeling is simultaneously suppressed, so resorption is uncoupled in
    both directions at once. This is the shared effector step this entry has
    in common with metabolic bone disease, and the reason the tumor's
    radiographic signature is purely lytic.
  biological_scale: TISSUE
  role: effector
  conforms_to: "osteoporosis_bone_resorption#Increased Osteoclastic Bone Resorption"
  cell_types:
  - preferred_term: Osteoclast-like multinucleated giant cell
    term:
      id: CL:0000092
      label: osteoclast
  biological_processes:
  - preferred_term: Bone resorption
    term:
      id: GO:0045453
      label: bone resorption
    modifier: INCREASED
  - preferred_term: Bone remodeling
    term:
      id: GO:0046849
      label: bone remodeling
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:22662295
    reference_title: 'Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A diverse array of inflammatory cytokines and chemokines disrupts
      osteoblastic differentiation and promotes the formation of excessive
      multi-nucleated osteoclastic cells.
    explanation: >-
      Captures both arms of the uncoupling curated here, suppressed osteoblastic
      differentiation alongside excessive osteoclast formation. Evidence source
      is OTHER because this is a review article.
  - reference: PMID:20149736
    reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Giant-cell tumour (GCT) of bone is a primary osteolytic bone tumour with
      low metastatic potential and is associated with substantial skeletal
      morbidity.
    explanation: >-
      Establishes the osteolytic character and skeletal morbidity that follow
      from unopposed resorption.
  downstream:
  - target: Locally Aggressive Osteolytic Tumor Mass
    causal_link_type: DIRECT
    description: >-
      Sustained resorption produces the expanding, cortex-thinning lytic lesion.
    evidence:
    - reference: PMID:20149736
      reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Giant-cell tumour (GCT) of bone is a primary osteolytic bone tumour with low metastatic potential and is associated with substantial skeletal morbidity.
      explanation: Characterizes the lesion produced by unopposed resorption as an osteolytic tumor causing skeletal morbidity.

- name: Locally Aggressive Osteolytic Tumor Mass
  description: >-
    The combined neoplastic and reactive compartments form an expanding
    epiphyseal-metaphyseal mass that erodes trabecular bone, thins and expands
    the cortex, and in advanced (Campanacci grade III) disease breaches it into
    the surrounding soft tissue. Subchondral extension threatens the adjacent
    joint. Secondary aneurysmal-bone-cyst-like change with blood-filled spaces
    is a common accompaniment. The mass, not any systemic effect, causes the
    disease's clinical phenotype: pain, swelling, restricted joint motion,
    pathologic fracture, and - in axial lesions - neural compression.
  biological_scale: TISSUE
  role: outcome
  evidence:
  - reference: PMID:29987945
    reference_title: 'Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Giant cell tumors of bone (GCT-B) are rare, locally aggressive tumors
      characterized by an abundance of giant cells.
    explanation: >-
      Characterizes the lesion as locally aggressive with abundant giant cells,
      the tissue-level outcome curated at this node.
  - reference: PMID:29987945
    reference_title: 'Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most common localization was the femur (35%), followed by the tibia (18%).
    explanation: >-
      Gives the nationwide-registry anatomical distribution of the tumor mass.
  downstream:
  - target: Local Recurrence After Incomplete Removal
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Residual mutant stroma left in the cavity after intralesional surgery
      regenerates the lesion.
    evidence:
    - reference: PMID:39236154
      reference_title: 'The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of Recurrence in 1,454 Patients.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Giant cell tumor of bone (GCTB) presents a challenge in management due to its invasive nature and propensity for local recurrence.
      explanation: States the propensity for local recurrence that follows from the tumor's invasive local behaviour.
  - target: Pulmonary Implantation of Histologically Benign Tumor
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A minority of tumors seed the lung, most strongly associated with local
      recurrence, high Campanacci stage, and curettage rather than resection.
    evidence:
    - reference: PMID:28443231
      reference_title: Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The recurrence rate, Campanacci stage, and surgical method were significant risk factors for lung metastasis.
      explanation: Identifies tumor stage and surgical handling as risk factors, which is the strongest evidence available here and the reason the target node carries mechanism_confidence PROVISIONAL rather than ESTABLISHED.

- name: Local Recurrence After Incomplete Removal
  description: >-
    Because the neoplastic stromal cells are histologically inconspicuous and
    diffusely distributed through the cavity wall, intralesional curettage
    reliably leaves some behind, and the tumor regrows. Recurrence is the
    dominant clinical problem in GCTB and the reason for high-speed burring,
    chemical or physical adjuvants, and cementation. It also raises the risk of
    the two rarer downstream outcomes, pulmonary implantation and malignant
    transformation.
  biological_scale: TISSUE
  role: outcome
  evidence:
  - reference: PMID:39236154
    reference_title: 'The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of Recurrence in 1,454 Patients.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall rate of recurrence for GCTB after intralesional curettage with
      BC was 20.05% vs. 29.74% with BG
    explanation: >-
      Quantifies post-curettage recurrence in a 1,454-patient meta-analysis for
      both cavity-filling strategies.
  - reference: PMID:21301899
    reference_title: 'The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median interval between initial surgery and the first recurrence of
      GCT was 16 months (2-180 months).
    explanation: >-
      Gives the timing of recurrence, supporting the surveillance interval
      implied by this node.
  - reference: PMID:21301899
    reference_title: 'The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Repeat recurrence also correlates with lung metastasis.
    explanation: >-
      Supports the curated edge from recurrence toward pulmonary implantation.
  downstream:
  - target: Pulmonary Implantation of Histologically Benign Tumor
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Repeated recurrence is among the strongest identified risk factors for
      lung involvement.
    evidence:
    - reference: PMID:21301899
      reference_title: 'The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Repeat recurrence also correlates with lung metastasis.
      explanation: Directly reports the association between repeat recurrence and lung involvement. The wording is correlational, matching the PROVISIONAL mechanism_confidence carried by the target node.

- name: Pulmonary Implantation of Histologically Benign Tumor
  mechanism_confidence: PROVISIONAL
  description: >-
    A minority of GCTBs produce lung nodules that are histologically identical
    to the primary tumor yet behave nothing like carcinomatous metastasis:
    survival remains near-normal, and spontaneous regression has been
    documented. Whether these represent true metastasis or mechanical
    embolization of tumor fragments during surgical manipulation is unresolved,
    which is why the curated confidence is PROVISIONAL and the node is named
    for implantation rather than metastasis. The observed risk factors - local
    recurrence, high Campanacci stage, and curettage over resection - are
    equally compatible with either reading.
  biological_scale: ORGANISM
  role: outcome
  evidence:
  - reference: PMID:28443231
    reference_title: Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The recurrence rate, Campanacci stage, and surgical method were
      significant risk factors for lung metastasis.
    explanation: >-
      Identifies the three risk factors curated in this node's description.
  - reference: PMID:28443231
    reference_title: Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 5-year overall survival rate was 94.4%."
    explanation: >-
      Quantifies the indolent behavior that distinguishes these deposits from
      conventional malignant metastasis.
  - reference: PMID:21301899
    reference_title: 'The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence of lung metastasis and malignant transformation were 7.5%
      (8 out of 107 patients) and 2.7% (3 out of 110 patients), respectively.
    explanation: >-
      Provides cohort frequencies for both rare outcomes curated in this entry.

- name: Malignant Sarcomatous Transformation
  mechanism_confidence: PROVISIONAL
  description: >-
    Rarely, GCTB progresses to a high-grade sarcoma, either arising alongside a
    conventional component (primary malignant GCTB) or years after treatment of
    a conventional tumor (secondary malignant GCTB). Transformation requires
    genetic events beyond the oncohistone: TP53 mutation with p53 nuclear
    accumulation, and loss of H3K27me3, are each found in subsets and appear
    mutually exclusive. Telomerase alterations are a distinct route, and carry a
    specific therapeutic implication - they render the neoplastic cells
    independent of osteoclasts for proliferation, predicting denosumab
    unresponsiveness. In a substantial fraction of cases the malignant component
    has lost the H3-3A G34W mutation the benign component carried, so the
    transformed tumor is not simply a more aggressive version of its precursor.
  biological_scale: CELLULAR
  role: outcome
  evidence:
  - reference: PMID:34785767
    reference_title: 'Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NGS on four MGCTBs revealed pathogenic mutations in TP53 (n = 3), EZH2
      (n = 1) and several other genes.
    explanation: >-
      Identifies the additional driver alterations found in malignant
      transformation.
  - reference: PMID:34785767
    reference_title: 'Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results suggested that p53 alteration and dysfunction of histone
      methylation as evidenced by H3K27me3 loss may play an important role in
      the malignant progression of GCTB
    explanation: >-
      States the two mechanistic routes to malignant progression curated at this
      node, with the authors' own hedging preserved.
  - reference: PMID:31285528
    reference_title: Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, in the remaining five cases, in contrast to their associated
      H3F3A G34W-mutant giant cell tumor, the sarcoma lacked the H3F3A G34W
      mutation, either entirely or sub-clonally in the samples tested.
    explanation: >-
      Documents loss of the founding driver in the malignant component, the
      basis for the claim that transformation is not simple progression.
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In contrast, hTERT alterations, commonly found in malignant GCT, result in
      the histone-mutated neoplastic cells being independent of osteoclasts for
      their proliferation, predicting unresponsiveness to denosumab.
    explanation: >-
      Supplies the telomerase route and its predicted consequence for
      RANKL-directed therapy, the mechanistic reason denosumab is not expected
      to control transformed disease.

phenotypes:
- category: Neoplasm
  name: Giant Cell Tumor of Bone
  description: >-
    The defining lesion: a geographic, purely osteolytic, eccentric
    epiphyseal-metaphyseal mass extending to subchondral bone in a skeletally
    mature patient. Present by definition in every affected individual.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Giant cell tumor of bone
    term:
      id: HP:0011847
      label: Giant cell tumor of bone
  evidence:
  - reference: PMID:29987945
    reference_title: 'Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Giant cell tumor of bone (GCT-B) is a locally aggressive neoplasm composed
      of sheets of mononuclear cells admixed with uniformly distributed large
      osteoclast-like giant cells, primarily affecting the metaphysis of long
      bones
    explanation: >-
      Describes the defining lesion and its characteristic long-bone location.

- category: Skeletal
  name: Localized Bone Pain
  description: >-
    Insidious pain at the affected site, developing over weeks to months, is
    the usual presenting symptom and reflects cortical thinning and periosteal
    stretching by the expanding lytic mass rather than any systemic process.
  phenotype_term:
    preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
    temporality: CHRONIC
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:21139931
    reference_title: 'The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with GCT of bone typically present with mechanical difficulty and
      pain as a result of bone destruction and are at an increased risk for
      fracture.
    explanation: >-
      Attributes the presenting pain and mechanical difficulty directly to bone
      destruction, and links it to fracture risk.
  - reference: PMID:28905737
    reference_title: Giant cell tumor of bone revisited.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Clinical symptoms are nonspecific and may include local pain, swelling,
      and limited range of motion of the adjacent joint.
    explanation: >-
      Names local pain first among the presenting symptoms. Evidence source is
      OTHER because this is a review article.
  notes: >-
    No frequency band is asserted. Pain is described as the typical presenting
    symptom in every source consulted, but none of the cached abstracts reports
    a proportion, and a FrequencyEnum value would be a quantitative claim the
    evidence does not make.

- category: Skeletal
  name: Pathologic Fracture
  description: >-
    Cortical thinning and destruction weaken the bone sufficiently that fracture
    may occur with trivial trauma, sometimes as the presenting event. Fracture
    complicates surgical decision-making, since the cavity is no longer
    contained.
  phenotype_term:
    preferred_term: Pathologic fracture
    term:
      id: HP:0002756
      label: Pathologic fracture
  evidence:
  - reference: PMID:21139931
    reference_title: 'The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with GCT of bone typically present with mechanical difficulty and
      pain as a result of bone destruction and are at an increased risk for
      fracture.
    explanation: >-
      States the increased fracture risk arising from tumor-mediated bone
      destruction.

- category: Musculoskeletal
  name: Local Swelling and Joint Effusion
  description: >-
    Because the tumor is characteristically juxta-articular, extending to the
    subchondral plate, local swelling and effusion at the adjacent joint are
    common presenting findings.
  phenotype_term:
    preferred_term: Joint swelling
    term:
      id: HP:0001386
      label: Joint swelling
  evidence:
  - reference: PMID:23378375
    reference_title: Giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Most patients present with pain, swelling, joint effusion, and disability
      in the third and fourth decades of life.
    explanation: >-
      Names swelling and joint effusion among the usual presenting findings.
      Evidence source is OTHER because this is a review article.

- category: Musculoskeletal
  name: Limitation of Joint Mobility
  description: >-
    Restricted range of motion at the joint adjacent to the tumor. Joint
    preservation is a central goal of management precisely because this tumor
    sits against the articular surface.
  phenotype_term:
    preferred_term: Limitation of joint mobility
    term:
      id: HP:0001376
      label: Limitation of joint mobility
  evidence:
  - reference: PMID:28905737
    reference_title: Giant cell tumor of bone revisited.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Clinical symptoms are nonspecific and may include local pain, swelling,
      and limited range of motion of the adjacent joint.
    explanation: >-
      Directly names limited range of motion of the adjacent joint among the
      presenting symptoms. Evidence source is OTHER because this is a review.

- category: Respiratory
  name: Pulmonary Nodules
  description: >-
    Nodules histologically identical to the primary tumor, usually multiple and
    frequently bilateral, most often peripherally located. Despite radiographic
    resemblance to metastatic disease, survival is near-normal.
  phenotype_term:
    preferred_term: Pulmonary nodule
    term:
      id: HP:0033608
      label: Pulmonary nodule
  evidence:
  - reference: PMID:28443231
    reference_title: Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eighteen patients had unilateral metastasis and 28 had bilateral
      metastasis. Most lesions (n=38) were located in the peripheral lung.
    explanation: >-
      Describes the laterality and peripheral distribution of the pulmonary
      deposits curated here.

- category: Neoplasm
  name: Secondary Sarcoma
  description: >-
    A high-grade sarcoma arising within or at the site of a giant cell tumor,
    most often osteosarcoma. Prognosis is that of the sarcoma, not of the
    original tumor.
  phenotype_term:
    preferred_term: Sarcoma
    term:
      id: HP:0100242
      label: Sarcoma
  evidence:
  - reference: PMID:21301899
    reference_title: 'The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence of lung metastasis and malignant transformation were 7.5%
      (8 out of 107 patients) and 2.7% (3 out of 110 patients), respectively.
    explanation: >-
      Reports the frequency of malignant transformation in a recurrent-GCT
      cohort.

- category: Skeletal
  name: Secondary Aneurysmal Bone Cyst Change
  description: >-
    Blood-filled cystic spaces developing within the tumor, producing
    fluid-fluid levels on MRI. This is a secondary change within a giant cell
    tumor, not a primary aneurysmal bone cyst, and the distinction matters
    because primary aneurysmal bone cyst is a differential diagnosis.
  phenotype_term:
    preferred_term: Aneurysmal bone cyst
    term:
      id: HP:0012063
      label: Aneurysmal bone cyst
  evidence:
  - reference: PMID:23708046
    reference_title: 'Giant cell tumor with secondary aneurysmal bone cyst: a unique presentation with an ossified extraosseous soft tissue mass.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI demonstrates a multiloculated lesion in the distal femur with multiple
      fluid-fluid levels and cortical penetration of the lesion.
    explanation: >-
      Human case documenting the multiple fluid-fluid levels that are the
      radiological signature of secondary aneurysmal bone cyst change within a
      giant cell tumor.
  - reference: PMID:21139758
    reference_title: Imaging of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Giant cell tumor can produce wide-ranging appearances depending on site,
      complications such as hemorrhage or pathological fracture and after
      surgical intervention.
    explanation: >-
      Imaging review noting that haemorrhagic complication changes the tumor's
      appearance, the general phenomenon of which secondary aneurysmal bone cyst
      change is the specific form. Evidence source is OTHER because this is a
      review article.
  - reference: PMID:41908959
    reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Both masses exhibited whitish areas interspersed with blood-filled spaces.
    explanation: >-
      The same blood-filled cystic change in the naturally occurring canine
      disease, recorded as a second, species-labelled observation rather than as
      the sole support for a human phenotype. Evidence source is MODEL_ORGANISM
      because the observation is in a dog.

- category: Neurological
  name: Spinal Cord or Nerve Root Compression
  description: >-
    Vertebral and sacral tumors compress neural structures, producing pain
    followed by neurological deficit. This anatomical subset accounts for much
    of the disease's serious morbidity and is where surgery is least feasible,
    making it the principal indication for denosumab.
  phenotype_term:
    preferred_term: Spinal cord compression
    term:
      id: HP:0002176
      label: Spinal cord compression
  evidence:
  - reference: PMID:21045974
    reference_title: 'Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most patients presented with pain or neurologic deficit at the site of
      tumor involvement, and symptoms were usually present for many months prior
      to diagnosis.
    explanation: >-
      Human series of 23 spinal and sacral giant cell tumors reporting
      neurological deficit as a usual presenting feature, with the insidious
      time course curated in this description.
  - reference: PMID:29745092
    reference_title: 'Therapeutic benefits of neoadjuvant and post-operative denosumab on sacral giant cell tumor: a retrospective cohort study of 30 cases.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A system (MUD system) proposed by our center was applied to score the
      sacral nerve deficit changes before surgery in group 3.
    explanation: >-
      A sacral giant cell tumor cohort in which nerve deficit is a scored
      clinical endpoint of neoadjuvant denosumab, supporting both the phenotype
      and the treatment rationale that depends on it.
  - reference: PMID:41908959
    reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Necropsy findings confirmed the presence of a nodular soft mass below the
      left kidney and a firm mass compressing the medullary canal at L1-L3.
    explanation: >-
      An explicit anatomical demonstration of neural-canal compression by a
      vertebral giant cell tumor, retained as a second observation alongside the
      human series. Evidence source is MODEL_ORGANISM because this is the canine
      case.

genetic:
- name: H3-3A
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: H3-3A
    term:
      id: hgnc:4764
      label: H3-3A
  variants:
  - name: H3-3A c.103G>T p.Gly34Trp
    type: MISSENSE
    description: >-
      The canonical oncohistone substitution. It does not raise the activity of
      a normal H3.3 function; it creates a chromatin behaviour wild-type H3.3
      does not have - impaired H3K36 trimethylation in cis and consequent
      genome-wide redistribution of H3K27me3 - so it is best read as neomorphic
      rather than as a simple gain of function.
    evidence:
    - reference: PMID:32967858
      reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        we show that H3.3K36me3 loss on mutant H3.3 alters the deposition of the
        repressive H3K27me3 mark from intergenic to genic regions, beyond areas
        of H3.3 deposition
      explanation: >-
        Describes the specific chromatin consequence of the substitution that
        makes it neomorphic rather than merely hyperactive.
  case_fractions:
  - population: Sequenced GCTB series, 180 cases
    case_fraction_percent: 90.56
    cohort_size: 180
    notes: >-
      G34W specifically; a further 4.4% carried G34L, G34V, or G34R, for 95.0%
      of cases mutated at codon 34 overall.
    evidence:
    - reference: PMID:33021329
      reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        DNA sequencing results revealed H3F3A mutations in 95.00% of GCTBs
        (171/180), including glycine 34 to tryptophan (G34W, 163/180, 90.56%),
        glycine 34 to leucine (G34L, 3/180, 1.67%), glycine 34 to valine (G34V,
        3/180, 1.67%), and glycine 34 to arginine (G34R, 2/180, 1.11%).
      explanation: >-
        Reports the per-variant case fractions in a 180-case sequenced series.
  evidence:
  - reference: PMID:24162739
    reference_title: Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mutations were restricted to the stromal cell population and were not
      detected in osteoclasts or their precursors.
    explanation: >-
      Establishes the somatic, stroma-restricted nature of the driver that this
      genetic entry records.
  - reference: PMID:32967858
    reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in
      approximately 90% of giant cell tumor of bone (GCT). Here, we show H3.3
      G34W is necessary for tumor formation.
    explanation: >-
      Demonstrates by genome editing that the variant is required for tumor
      formation, supporting SOMATIC_DRIVER rather than a bystander annotation.
  notes: >-
    The somatic driver of conventional GCTB, confined to the neoplastic stromal
    cells. Because it is somatic and tumor-restricted it carries no recurrence
    risk for relatives and is not a germline testing target; its clinical role
    is diagnostic, through mutation-specific immunohistochemistry or sequencing.

- name: TP53
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  evidence:
  - reference: PMID:34785767
    reference_title: 'Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunohistochemical analysis of the nine MGCTBs confirmed the p53 nuclear
      accumulation (n = 5) and loss of H3K27me3 expression (n = 3) and showed
      that they were mutually exclusive.
    explanation: >-
      Documents both progression routes and their mutual exclusivity in
      malignant giant cell tumor of bone.
  notes: >-
    Not involved in conventional GCTB. TP53 mutation with p53 nuclear
    accumulation is one of two routes associated with progression to malignant
    giant cell tumor of bone, and appears mutually exclusive with the
    H3K27me3-loss route. Scoped to malignant transformation only; curating this
    as a driver of conventional GCTB would be wrong.

- name: TERT
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: TERT
    term:
      id: hgnc:11730
      label: TERT
  evidence:
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In contrast, hTERT alterations, commonly found in malignant GCT, result in
      the histone-mutated neoplastic cells being independent of osteoclasts for
      their proliferation, predicting unresponsiveness to denosumab.
    explanation: >-
      States both the association with malignant GCT and the loss of osteoclast
      dependence that carries the therapeutic implication.
  notes: >-
    Telomerase alterations are found in malignant GCTB and define a biologically
    distinct route: they free the histone-mutated neoplastic cells from their
    dependence on osteoclasts for proliferation, which is the mechanistic
    prediction that such tumors will not respond to RANKL blockade.

- name: TNFSF11
  relationship_type: BIOMARKER
  gene_term:
    preferred_term: TNFSF11
    term:
      id: hgnc:11926
      label: TNFSF11
  evidence:
  - reference: PMID:20149736
    reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GCT is rich in osteoclast-like giant cells and contains mononuclear
      (stromal) cells that express RANK ligand (RANKL), a key mediator of
      osteoclast activation.
    explanation: >-
      Records stromal RANKL expression, the basis for treating this gene as a
      mechanistic and therapeutic marker rather than a mutated driver.
  notes: >-
    RANKL. Not mutated in GCTB; it is overexpressed by the neoplastic stromal
    cells as a consequence of the oncohistone-driven transcriptional program,
    and it is the drug target that defines modern systemic therapy for this
    disease.

- name: SCUBE3
  relationship_type: BIOMARKER
  gene_term:
    preferred_term: SCUBE3
    term:
      id: hgnc:13655
      label: SCUBE3
  evidence:
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Transcriptional changes in SCUBE3 are associated with altered histone
      marks and H3.3G34W enrichment at its enhancer regions.
    explanation: >-
      Ties reduced SCUBE3 expression to mutant-H3.3 occupancy at its enhancers.
  notes: >-
    Epigenetically repressed rather than mutated. Mutant H3.3 enrichment at
    SCUBE3 enhancers reduces expression of its secreted TGF-beta-like product,
    removing a restraint on osteoclast recruitment.

- name: SEMA4D
  relationship_type: BIOMARKER
  gene_term:
    preferred_term: SEMA4D
    term:
      id: hgnc:10732
      label: SEMA4D
  evidence:
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances
      proliferation of mutated osteoprogenitors arresting their maturation.
    explanation: >-
      Documents the osteoclast-derived signal and its effect on the neoplastic
      compartment.
  notes: >-
    Secreted by the reactive osteoclast compartment, not by the tumor cells.
    SEMA4D drives proliferation of the mutant osteoprogenitors and holds their
    maturation in arrest, closing the paracrine loop.

histopathology:
- name: Osteoclast-Like Multinucleated Giant Cells on a Mononuclear Background
  description: >-
    The diagnostic histology is a uniform distribution of very large
    multinucleated osteoclast-like giant cells, often with dozens of nuclei,
    scattered evenly through sheets of mononuclear cells. The mononuclear
    population is itself two populations that light microscopy does not
    separate: reactive monocyte-macrophage lineage cells, and the spindled
    neoplastic stromal cells that carry the mutation. Even distribution of the
    giant cells is a useful discriminator from other giant-cell-rich lesions,
    where they tend to cluster.
  diagnostic: true
  evidence:
  - reference: PMID:29987945
    reference_title: 'Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Giant cell tumor of bone (GCT-B) is a locally aggressive neoplasm composed
      of sheets of mononuclear cells admixed with uniformly distributed large
      osteoclast-like giant cells, primarily affecting the metaphysis of long
      bones
    explanation: >-
      Describes the sheets of mononuclear cells with uniformly distributed giant
      cells that define the histology.
  - reference: PMID:23378375
    reference_title: Giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mononuclear stromal cells are the physiologically active and diagnostic
      cell type.
    explanation: >-
      Identifies the mononuclear stromal cell rather than the giant cell as the
      biologically decisive population. Evidence source is OTHER because this is
      a review article.

- name: H3.3 G34W Mutant-Protein Immunoreactivity
  description: >-
    Nuclear staining with a mutation-specific antibody in the neoplastic
    mononuclear cells, absent from the giant cells - immunohistochemistry that
    directly visualizes the compartment restriction of the driver. It has
    become the practical diagnostic discriminator against giant-cell-rich
    mimics. Discordance in both directions exists: rare tumors stain positive
    without a detectable mutation, and sequencing can be falsely negative when
    neoplastic cells are sparse in the sample.
  diagnostic: true
  evidence:
  - reference: PMID:33021329
    reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunohistochemistry showed that GCTBs harboring G34W also expressed the
      mutant protein in tumor cell nuclei.
    explanation: >-
      Establishes concordance between the mutation and nuclear mutant-protein
      staining in tumor cells.
  - reference: PMID:33021329
    reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although DNA sequencing analysis detected rare mutation types of H3F3A,
      false-negative results were also present due to the small number of cells
      in the samples.
    explanation: >-
      Documents the sequencing false-negative mode caused by low neoplastic-cell
      content. Recorded as PARTIAL because it qualifies the assay rather than
      supporting it.
  - reference: PMID:35837707
    reference_title: Updated concepts in treatment of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The most frequent mutation (G34W) can be detected using
      immunohistochemistry and is highly specific in differentiating GCTB from
      other giant cell containing tumors.
    explanation: >-
      Supports the diagnostic discriminating role of the immunohistochemical
      stain. Evidence source is OTHER because this is a review article.

prevalence:
- population: Netherlands, nationwide pathology registry 2009-2013
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_per_100000: 0.17
  notes: >-
    1.7 per million inhabitants per year, converted to 0.17 per 100,000. The
    first incidence estimate from a pathology database with complete national
    coverage, so it is less subject to the referral bias of doctor-driven
    registries.
  evidence:
  - reference: PMID:29987945
    reference_title: 'Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For GCT-B the incidence was 1.7 per million inhabitants per year with a
      male to female ratio of 1:1.38 and a median age of 35 years (9-77).
    explanation: >-
      Provides the incidence rate, sex ratio, and age distribution recorded
      here.

- population: United States, SEER 1975-2004, malignant giant cell tumor only
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_per_100000: 0.016
  notes: >-
    1.6 per 10,000,000 per year for the malignant form specifically, roughly a
    tenth of the incidence of conventional GCTB. Do not compare this figure
    with the Dutch rate above as though they measured the same thing.
  evidence:
  - reference: PMID:21139931
    reference_title: 'The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on analyses of 117 malignant GCT cases, the estimated annual
      incidence in the United States was 1.6 per 10,000,000 persons per year.
    explanation: >-
      Population-based SEER incidence estimate for malignant giant cell tumor.

progression:
- phase: Local growth, treatment, and surveillance for recurrence
  notes: >-
    The usual course is a single episode of insidious local growth over months,
    surgical treatment, and then a surveillance period dominated by recurrence
    risk. Recurrence clusters early - median around 16 months - which sets the
    intensity of early follow-up, though the reported range extends to 15
    years. Chest surveillance runs in parallel because pulmonary deposits
    appear later and are strongly associated with recurrence. Malignant
    transformation is a late and rare event.
  evidence:
  - reference: PMID:21301899
    reference_title: 'The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median interval between initial surgery and the first recurrence of
      GCT was 16 months (2-180 months).
    explanation: >-
      Gives the timing and spread of first recurrence that shapes the
      surveillance schedule.
  - reference: PMID:21301899
    reference_title: 'The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early local recurrence of GCT is a risk factor for repeat recurrence.
    explanation: >-
      Establishes that early recurrence predicts further recurrence, the basis
      for intensified follow-up after a first relapse.

treatments:
- name: Extended Intralesional Curettage with Adjuvant and Cementation
  description: >-
    The standard operation for most Campanacci grade I and II lesions:
    curettage of the cavity, high-speed burring of its walls, a chemical or
    physical adjuvant, and filling with polymethylmethacrylate bone cement or
    bone graft. It preserves the joint at the cost of a substantial recurrence
    rate, because the neoplastic stroma is inconspicuous and diffuse.
    Meta-analytic evidence favours cement over graft for local control, though
    recurrence remains high either way, and a distal-radius meta-analysis found
    no cement advantage in that site - so the choice is not settled across all
    locations.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: curettage procedure
    term:
      id: NCIT:C15216
      label: Curettage Procedure
  target_mechanisms:
  - target: Locally Aggressive Osteolytic Tumor Mass
    treatment_effect: INHIBITS
    description: >-
      Physically removes the tumor mass while preserving the adjacent joint.
    evidence:
    - reference: PMID:39236154
      reference_title: 'The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of Recurrence in 1,454 Patients.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        While either bone grafting (BG) or bone cement (BC) can be utilized to
        fill defects after intralesional curettage, the optimal treatment
        remains contested.
      explanation: >-
        Describes the procedure acting directly on the tumor cavity, the mass
        node this link targets.
  evidence:
  - reference: PMID:39236154
    reference_title: 'The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of Recurrence in 1,454 Patients.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intralesional curettage with BG had a recurrence risk ratio of 1.68 (95%
      confidence interval [CI], 1.22-2.31, p = 0.001) when compared with BC.
    explanation: >-
      Quantifies the cement-versus-graft difference in a 1,454-patient
      meta-analysis: curettage plus bone graft carries a 68% higher recurrence
      risk than curettage plus cement.
  - reference: PMID:39236154
    reference_title: 'The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of Recurrence in 1,454 Patients.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, the rates of recurrence remain substantial for both groups,
      necessitating careful consideration of the benefits and potential pitfalls
      associated with BC vs. BG when considering salvage options after
      recurrences.
    explanation: >-
      Supports the procedure while explicitly qualifying it: recurrence stays
      substantial regardless of filler, which is why this is PARTIAL.
  - reference: PMID:22773395
    reference_title: Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The use of PMMA versus bone graft did not affect the recurrence rate (RR,
      0.98; 95% CI, 0.44-2.17).
    explanation: >-
      A distal-radius meta-analysis that did not reproduce the cement advantage,
      recorded as PARTIAL because it qualifies the general recommendation by
      anatomical site.

- name: En Bloc Wide Resection
  description: >-
    Complete removal with a margin of normal tissue, giving markedly better
    local control than curettage at the cost of joint sacrifice and a
    reconstruction. Reserved for Campanacci grade III lesions, extensively
    destructive tumors, and some recurrences - the trade is fewer recurrences
    for more major complications, and the balance shifts with grade.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  target_mechanisms:
  - target: Local Recurrence After Incomplete Removal
    treatment_effect: INHIBITS
    description: >-
      Removing the lesion with a margin eliminates the residual mutant stroma
      that drives recurrence after intralesional surgery.
    evidence:
    - reference: PMID:22773395
      reference_title: Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Overall, patients in the intralesional excision group had a higher
        recurrence rate (relative risk [RR], 2.80; 95% CI, 1.17-6.71),
        especially for Campanacci grade 3 GCTs (RR, 4.90; 95% CI, 1.36-17.66)
      explanation: >-
        Quantifies the recurrence advantage of resection over intralesional
        excision, largest in high-grade tumors, the effect this mechanism link
        asserts.
  evidence:
  - reference: PMID:22773395
    reference_title: Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Overall, patients in the intralesional excision group had a higher
      recurrence rate (relative risk [RR], 2.80; 95% CI, 1.17-6.71), especially
      for Campanacci grade 3 GCTs (RR, 4.90; 95% CI, 1.36-17.66), yet fewer
      major complications (RR, 0.21; 95% CI, 0.09-0.54) than the en bloc
      resection group.
    explanation: >-
      Quantifies both sides of the trade-off, the far higher recurrence risk of
      intralesional excision overall and for Campanacci grade 3 tumors in
      particular, and the lower rate of major complications that is its
      counterweight.
  - reference: PMID:22773395
    reference_title: Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intralesional excision appears to be more appropriate for the treatment of
      local lesions (e.g., grades 1 and 2) than grade 3 GCTs of the distal
      radius
    explanation: >-
      States the grade-dependent selection rule that assigns resection to
      higher-grade disease.

- name: Denosumab
  description: >-
    A fully human monoclonal antibody against RANKL, and the clearest example
    in this entry of a mechanism-directed therapy. By blocking RANKL it starves
    the reactive osteoclast compartment, eliminating the giant cells and
    halting resorption; the arrested stroma then differentiates and new bone
    forms in the lesion. It permits surgery to be downstaged or deferred in
    tumors that would otherwise require a morbid operation, and it is the
    principal option in unresectable axial disease. Two limits follow directly
    from the mechanism: it does not eliminate the mutant stroma, so tumors
    regrow when it stops; and tumors that have escaped osteoclast dependence
    through telomerase alterations are predicted not to respond.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: denosumab
      term:
        id: NCIT:C61313
        label: Denosumab
  target_mechanisms:
  - target: Stromal RANKL Overexpression
    treatment_effect: INHIBITS
    description: >-
      Denosumab binds RANKL directly, preventing engagement of RANK on
      osteoclast precursors. This is the node the drug occupies.
    evidence:
    - reference: PMID:20149736
      reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We investigated the potential therapeutic effect of denosumab, a fully
        human monoclonal antibody against RANKL, on tumour-cell survival and
        growth in patients with GCT.
      explanation: >-
        Identifies RANKL as the molecular target of the antibody, matching the
        curated mechanism node.
  - target: Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells
    treatment_effect: INHIBITS
    description: >-
      Downstream of RANKL blockade the giant cells are depleted, which is how
      histological response was defined in the first trial.
    evidence:
    - reference: PMID:20149736
      reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The primary endpoint was tumour response, defined as elimination of at
        least 90% of giant cells or no radiological progression of the target
        lesion up to week 25.
      explanation: >-
        Shows that giant cell elimination is the measured effect of the drug,
        supporting this specific mechanism link.
  evidence:
  - reference: PMID:20149736
    reference_title: 'Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      30 of 35 (86%; 95% CI 70-95) of evaluable patients had a tumour response:
      20 of 20 assessed by histology and 10 of 15 assessed by radiology.
    explanation: >-
      Quantifies the response rate in the proof-of-concept phase 2 study.
  - reference: PMID:26033180
    reference_title: Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the data cutoff date, most patients had not yet undergone surgery
      (n = 106; 48 %) or had a less morbid procedure (n = 84; 38 %) than
      originally planned.
    explanation: >-
      Documents the surgical-downstaging benefit that is the main reason for
      neoadjuvant use.
  - reference: PMID:31704134
    reference_title: 'Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      28 (5%) patients had positively adjudicated osteonecrosis of the jaw, four
      (1%) had atypical femur fracture, and four (1%) had hypercalcaemia
      occurring 30 days after denosumab discontinuation.
    explanation: >-
      The large phase 2 safety dataset. Recorded as PARTIAL because it reports
      the toxicity that bounds long-term use rather than efficacy.
  - reference: PMID:31704134
    reference_title: 'Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      227 (92%; 95% CI 87-95) of 248 patients who received at least one dose of
      denosumab in cohort 2 had no surgery in the first 6 months of the study.
    explanation: >-
      Quantifies surgery avoidance in the surgically salvageable cohort.
  notes: >-
    Approved for adults and skeletally mature adolescents with unresectable
    GCTB, or where surgery would cause severe morbidity. Whether neoadjuvant
    denosumab raises post-curettage recurrence is genuinely unsettled and is
    curated as an explicit discussion below rather than asserted here.

- name: Zoledronic Acid
  description: >-
    A bisphosphonate used as a systemic or cement-loaded local adjuvant. Its
    mechanism in GCTB is not the same as denosumab's: in cell-line work it
    directly inhibits growth of and induces apoptosis in the neoplastic stromal
    cells, whereas denosumab does neither. That difference makes it
    conceptually attractive as an adjuvant against the compartment denosumab
    leaves behind, but the clinical evidence is small-trial and meta-analytic
    rather than definitive, so it is curated as a supported adjunct and not as
    standard of care.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: zoledronic acid
      term:
        id: CHEBI:46557
        label: zoledronic acid
  target_mechanisms:
  - target: Arrested Osteogenic Differentiation of the Neoplastic Stroma
    treatment_effect: INHIBITS
    description: >-
      Zoledronic acid acts on the neoplastic stromal compartment itself,
      inhibiting growth and inducing apoptosis in cell lines - the compartment
      that RANKL blockade does not touch.
    evidence:
    - reference: PMID:24060052
      reference_title: Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        ZOL was found to exhibit a dose-dependent inhibition in cell growth in
        all GCT stromal cell lines tested and cause apoptosis in two out of
        three cell lines.
      explanation: >-
        Demonstrates a direct anti-stromal effect, the basis for targeting this
        mechanism node rather than the RANKL node.
  evidence:
  - reference: PMID:32541321
    reference_title: Current concepts in the treatment of giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Also, the bisphosphonate zoledronic acid has activity in GCTB by directly
      targeting the neoplastic stromal cells.
    explanation: >-
      States the drug's activity and its stromal target. Evidence source is
      OTHER because this is a review article.
  - reference: PMID:32541321
    reference_title: Current concepts in the treatment of giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In a small RCT, bisphosphonates were successful in controlling tumour
      growth and a higher apoptotic index of tumour cells was seen after
      zoledronic acid versus controls.
    explanation: >-
      The clinical support is a small randomized trial, so this is recorded as
      PARTIAL rather than SUPPORT. Evidence source is OTHER because the citing
      article is a review.

- name: Radiation Therapy
  description: >-
    Reserved for tumors that cannot be resected and where denosumab,
    bisphosphonates, and embolization are unavailable or have failed - largely
    spinal and sacral disease. The reason for that narrow indication is
    mechanistic rather than merely one of efficacy: irradiation is itself
    associated with later sarcomatous transformation of a tumor whose baseline
    transformation risk is already the most feared outcome.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
  target_mechanisms:
  - target: Locally Aggressive Osteolytic Tumor Mass
    treatment_effect: INHIBITS
    description: >-
      Achieves local control of an unresectable mass.
  evidence:
  - reference: PMID:21139931
    reference_title: 'The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malignant giant cell tumor (GCT) of bone is a rare tumor with debilitating
      consequences.
    explanation: >-
      Establishes the severity of the malignant outcome that motivates
      restricting radiotherapy. Recorded as PARTIAL because it characterizes
      the risk this treatment is limited by, not the treatment's efficacy.
  notes: >-
    A quotable statement of the radiotherapy-to-sarcoma association from a
    cached abstract was not identified in this curation pass. The association is
    long-standing in the literature and is the stated reason for restricting the
    modality; it is left as description and notes rather than attached to a
    snippet that does not say it.

- name: Embolization Therapy
  description: >-
    Selective arterial embolization, used preoperatively to reduce blood loss
    during surgery on a highly vascular tumor and, in some inoperable axial
    lesions, as a primary modality.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: embolization therapy
    term:
      id: NCIT:C15230
      label: Embolization Therapy
  target_mechanisms:
  - target: Locally Aggressive Osteolytic Tumor Mass
    treatment_effect: INHIBITS
    description: >-
      Devascularizes the tumor mass.
    evidence:
    - reference: PMID:21045974
      reference_title: 'Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        One sacral GCT patient was treated only with serial arterial embolization
        with good disease control.
      explanation: >-
        Embolization alone controlled the tumor mass in a patient who received no
        other treatment, the clearest available demonstration that
        devascularization acts on this node rather than merely assisting surgery.
  evidence:
  - reference: PMID:21045974
    reference_title: 'Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Six of the sacral GCT patients were treated with pre-operative arterial
      embolization and intralesional surgical resection, and two developed a
      recurrence.
    explanation: >-
      Documents the preoperative-adjunct use of embolization in sacral disease,
      the setting in which this treatment is standard practice.
  - reference: PMID:21045974
    reference_title: 'Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      conservative therapy involving arterial embolization and intralesional
      resection offers the best results.
    explanation: >-
      The authors' conclusion favouring embolization plus intralesional
      resection. Recorded as PARTIAL because the same abstract also concludes
      that en bloc resection should be preferred whenever possible, so this
      statement is a qualified recommendation for the sacral subset rather than
      a general one.
  notes: >-
    Evidence was attached on re-review. The earlier note recorded that no cached
    abstract stated the practice in quotable form; PMID:21045974, fetched in the
    same commit for the spinal-compression phenotype, does - a reminder that a
    "no evidence available" note can go stale the moment the cache grows, and
    should be re-checked rather than trusted.

differential_diagnoses:
- name: Chondroblastoma
  description: >-
    The other epiphyseal giant-cell-rich bone tumor, and the sharpest
    mechanistic contrast in this entry: it is driven by a p.Lys36Met
    substitution in H3-3B rather than p.Gly34Trp in H3-3A. The two oncohistone
    lesions are mutually exclusive and tumor-type specific, so the molecular
    test separates them definitively. Clinically, chondroblastoma occurs before
    physeal closure, whereas GCTB occurs after.
  distinguishing_features:
  - Driven by H3-3B p.Lys36Met rather than H3-3A p.Gly34Trp
  - Occurs in the skeletally immature, before physeal closure
  - Negative for H3.3 G34W mutant-protein immunohistochemistry
  evidence:
  - reference: PMID:24162739
    reference_title: Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 73 of 77 cases of chondroblastoma (95%), we found p.Lys36Met
      alterations predominantly encoded in H3F3B, which is one of two genes for
      histone H3.3.
    explanation: >-
      Establishes the distinct driver alteration and gene that separate
      chondroblastoma from GCTB.
  - reference: PMID:33021329
    reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other bone tumors all showed wild-type expression in both DNA sequencing
      and immunohistochemistry.
    explanation: >-
      Confirms that the non-GCTB tumors in the series, chondroblastoma among
      them, were negative by both assays.

- name: Tenosynovial Giant Cell Tumor
  description: >-
    Shares the words "giant cell tumor" and nothing mechanistic. TGCT arises
    from joints, bursae, and tendon sheaths rather than bone, and is driven by
    CSF1 rather than an oncohistone - so its targeted therapy is CSF1R
    inhibition, not RANKL blockade. Conflating the two is a real risk when
    searching the literature by name.
  distinguishing_features:
  - Arises from synovium, bursa, or tendon sheath rather than within bone
  - CSF1-driven, treated with CSF1R inhibitors rather than anti-RANKL antibody
  - Not associated with H3-3A p.Gly34Trp
  evidence:
  - reference: PMID:36502615
    reference_title: 'Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive,
      mesenchymal tumor arising from the joints, bursa and tendon sheaths.
    explanation: >-
      Establishes the distinct anatomical origin that separates TGCT from a
      primary bone tumor. Evidence source is OTHER because this is a consensus
      paper.
  - reference: PMID:36502615
    reference_title: 'Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      CSFR1 inhibitors are effective with benefit on symptoms and QoL but are
      not available in most countries.
    explanation: >-
      Documents the entirely different drug target, the practical consequence of
      confusing the two entities. Evidence source is OTHER because this is a
      consensus paper.

- name: Aneurysmal Bone Cyst
  description: >-
    A blood-filled cystic lytic lesion that both mimics GCTB radiographically
    and occurs as a secondary change within one. Fluid-fluid levels on MRI
    favour it, but their presence does not exclude a giant cell tumor with
    secondary cystic change - which is why the H3.3 G34W stain matters here.
  distinguishing_features:
  - Fluid-fluid levels on MRI, though these also occur in GCTB with secondary cystic change
  - Negative for H3.3 G34W mutant-protein immunohistochemistry
  evidence:
  - reference: PMID:33021329
    reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other bone tumors all showed wild-type expression in both DNA sequencing
      and immunohistochemistry.
    explanation: >-
      The nine aneurysmal bone cysts in this series were among the non-GCTB
      tumors negative by both assays, supporting the molecular discriminator.

- name: Malignant Giant Cell Tumor of Bone
  description: >-
    Not a mimic but a progression, and the distinction that changes management
    most. A high-grade sarcoma arising primarily alongside or secondarily at the
    site of a conventional tumor. It may retain or lose the H3.3 G34W stain, so
    a negative stain in a giant-cell-rich sarcoma does not exclude it.
  distinguishing_features:
  - High-grade sarcomatous histology, most often osteosarcoma
  - May carry TP53 mutation or loss of H3K27me3
  - The H3-3A G34W mutation is lost in a substantial fraction of malignant components
  evidence:
  - reference: PMID:31285528
    reference_title: Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, in the remaining five cases, in contrast to their associated
      H3F3A G34W-mutant giant cell tumor, the sarcoma lacked the H3F3A G34W
      mutation, either entirely or sub-clonally in the samples tested.
    explanation: >-
      Documents the mutation loss that makes a negative stain uninformative for
      excluding malignant transformation.

clinical_trials:
- name: NCT00680992
  phase: PHASE_II
  status: COMPLETED
  description: >-
    The pivotal open-label multicentre phase 2 study of denosumab in GCTB, 532
    patients across 30 sites in 12 countries, which established the safety
    profile and long-term disease control underpinning approval. Its published
    results are curated as PMID:31704134.
  target_phenotypes:
  - preferred_term: Giant cell tumor of bone
    term:
      id: HP:0011847
      label: Giant cell tumor of bone
  evidence:
  - reference: clinicaltrials:NCT00680992
    reference_title: An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To determine how safe denosumab is in treating subjects with giant cell
      tumor of bone (GCTB)
    explanation: >-
      States the trial's objective, confirming it as the denosumab safety study
      in this disease.

- name: NCT00889590
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    Randomised phase 2 trial of adjuvant zoledronic acid in high-risk GCTB,
    testing whether systemic bisphosphonate lowers the 2-year recurrence rate
    against standard care. Directly tests the anti-stromal rationale curated on
    the zoledronic acid treatment entry.
  target_phenotypes:
  - preferred_term: Giant cell tumor of bone
    term:
      id: HP:0011847
      label: Giant cell tumor of bone
  evidence:
  - reference: clinicaltrials:NCT00889590
    reference_title: Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Determine if adjuvant zoledronic acid improves the 2 years recurrence rate
      of 'high risk' GCT as compared to standard care
    explanation: >-
      States the primary objective, the recurrence endpoint this entry's
      recurrence node is concerned with.
  notes: >-
    `status: UNKNOWN` because the cached ClinicalTrials.gov summary does not
    report a recruitment status.

- name: NCT05595603
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    Randomised trial of zoledronic-acid-loaded bone cement as a local adjuvant
    after intralesional curettage. The local-delivery design is the direct
    response to the recurrence problem curated at the curettage treatment
    entry: it aims at the residual mutant stroma in the cavity wall while
    avoiding systemic bisphosphonate exposure.
  target_phenotypes:
  - preferred_term: Giant cell tumor of bone
    term:
      id: HP:0011847
      label: Giant cell tumor of bone
  evidence:
  - reference: clinicaltrials:NCT05595603
    reference_title: 'Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage: a Prospective, Multicenter, Single Blinded, Randomized Control Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The purpose of this study is to investigate whether zoledronic acid-loaded
      bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease
      local recurrence in patients with giant cell bone tumor following
      intralesional curettage surgery.
    explanation: >-
      States the intervention and the local-recurrence endpoint.
  notes: >-
    `phase: NOT_APPLICABLE` because this is a device/local-delivery adjuvant
    trial that does not follow the standard drug-phase classification;
    `status: UNKNOWN` because the cached summary does not report one.

datasets:
- accession: geo:GSE168664
  title: Single-cell RNA sequencing of human giant cell tumor of bone
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 1
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: >-
    Single-cell resolution of the tripartite GCTB ecosystem. Relevant because
    the disease's central claim is about cross-talk between compartments that
    bulk profiling cannot separate. Triaged as directly on-disease: the series
    title names giant cell tumor of bone and the material is human tumor.

- accession: geo:GSE254672
  title: >-
    Single cell sequencing reveals the immunosuppressive trajectory in the tumor
    microenvironment of human giant cell tumor
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 1
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: >-
    Microenvironment-focused single-cell data. Triaged as directly on-disease
    from the series title.

- accession: geo:GSE206448
  title: RNA-Seq analysis for giant cell tumour of the bone
  data_type: BULK_RNA_SEQ
  sample_count: 10
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: Bulk transcriptomes of human giant cell tumor of bone.

- accession: geo:GSE148616
  title: >-
    Gene expression profile of human osteoclastoma bone tumor derived giant
    osteoclast cells
  data_type: MICROARRAY
  sample_count: 2
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: >-
    Profiles the giant osteoclast compartment specifically, which is the
    reactive rather than neoplastic population - the one distinction this entry
    turns on. Small (n=2), so it is a resource pointer rather than a basis for
    quantitative claims. "Osteoclastoma" is the historical synonym for this
    disease, not a different entity.

experimental_models:
- name: Patient-derived GCTB stromal cell culture
  description: >-
    Primary mononuclear stromal cells outgrown from surgical GCTB specimens,
    carrying the endogenous H3.3-G34W mutation at physiological expression
    levels. This is the workhorse system of the field: essentially all
    mechanistic knowledge of the oncohistone's chromatin effects, the
    osteogenic differentiation block, and the SCUBE3/SEMA4D paracrine axis
    derives from it.
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_source: Surgical giant cell tumor of bone specimens
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:33110075
  evidence:
  - reference: PMID:33110075
    reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a
      mutation in H3F3A, leading to a mutant histone variant, H3.3-G34W, as a
      sole recurrent genetic alteration.
    explanation: >-
      Establishes that cells cultured from GCTB specimens carry the
      disease-defining lesion, which is what makes this culture system a valid
      model of the human disease.
  modeled_mechanisms:
  - target: Genome-Wide Epigenetic Reprogramming by Mutant Histone H3.3
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the chromatin incorporation of mutant H3.3 and the genome-wide
      DNA methylation, accessibility, and histone-mark changes in cells carrying
      the endogenous mutation.
    limitations: >-
      Cultured stromal cells are isolated from the osteoclast compartment and
      bone matrix that shape their behaviour in vivo, so the paracrine loop
      curated in this entry cannot operate in monoculture. Outgrowth also
      selects for proliferative cells, and the differentiation stage of the
      cultured population is itself a confounder the source study raises.
    readouts:
    - name: Genome-wide DNA methylation, chromatin accessibility, and histone modification profiles
      target: Genome-Wide Epigenetic Reprogramming by Mutant Histone H3.3
      direction: ALTERED
      interpretation: >-
        Multi-layer epigenomic profiling is the measurement that grounds this
        node.
      evidence:
      - reference: PMID:33110075
        reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          in patient-derived stromal cells H3.3-G34W is incorporated into the
          chromatin and associates with massive epigenetic alterations on the
          DNA methylation, chromatin accessibility and histone modification
          level
        explanation: >-
          Names the three measurement layers reported for this readout.
    evidence:
    - reference: PMID:33110075
      reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        These epigenetic alterations affect mainly heterochromatic and bivalent
        regions and provide possible explanations for the genomic instability,
        as well as the osteolytic phenotype of GCTB.
      explanation: >-
        Reports what the model shows about this node and how the authors connect
        it to the disease phenotype.
  - target: Arrested Osteogenic Differentiation of the Neoplastic Stroma
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Mutant patient-derived cells show impaired osteogenic differentiation
      under differentiation conditions.
    limitations: >-
      Differentiation assays are driven by supraphysiological osteogenic media
      rather than the in vivo niche, and the source study frames the finding as
      a delay in differentiation stage, which is a weaker claim than a
      permanent block.
    readouts:
    - name: Osteogenic differentiation capacity of mutant versus wild-type stromal cells
      target: Arrested Osteogenic Differentiation of the Neoplastic Stroma
      direction: DECREASED
      interpretation: >-
        Reduced osteogenic differentiation is the direct cellular correlate of
        the differentiation-block node.
      evidence:
      - reference: PMID:33110075
        reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The mutation occurs in differentiating mesenchymal stem cells and
          associates with an impaired osteogenic differentiation.
        explanation: >-
          Reports the measured impairment of osteogenic differentiation.
    evidence:
    - reference: PMID:33110075
      reference_title: Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We propose that the observed epigenetic alterations reflect distinct
        differentiation stages of H3.3 WT and H3.3 MUT stromal cells
      explanation: >-
        The authors' own framing of what the model shows, preserved with its
        hedging. Recorded as PARTIAL because it qualifies the differentiation
        claim rather than simply confirming it.

- name: CRISPR-Cas9 H3.3 G34W-edited GCTB tumor-derived cells
  description: >-
    Tumor-derived cells in which the G34W allele is introduced or removed by
    genome editing. This is what converts the mutation from a correlate into a
    demonstrated requirement, and it is the only system in which necessity for
    tumor formation has been tested.
  experimental_model_type: CELL_LINE
  cell_source: GCTB tumor-derived cells edited for H3.3 G34W
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:32967858
  evidence:
  - reference: PMID:32967858
    reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      By profiling the epigenome, transcriptome, and secreted proteome of
      patient samples and tumor-derived cells CRISPR-Cas9-edited for H3.3 G34W
    explanation: >-
      Describes the edited tumor-derived system and the multi-omic profiling
      that establish it as a model of the driver mutation.
  modeled_mechanisms:
  - target: Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells
    relationship: PERTURBS
    fidelity: HIGH
    description: >-
      Directly manipulates the driver allele, establishing that G34W is
      necessary for tumor formation rather than merely associated with it.
    limitations: >-
      Editing is performed in established tumor-derived cells that already carry
      the tumor's other acquired changes, so the experiment tests the mutation's
      requirement for maintaining the transformed state more directly than its
      sufficiency to initiate one in a normal mesenchymal progenitor.
    readouts:
    - name: Tumor formation by G34W-edited versus unedited cells
      target: Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells
      direction: ABOLISHED
      interpretation: >-
        Loss of tumor formation on removing the allele is the necessity test.
      evidence:
      - reference: PMID:32967858
        reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Glycine 34-to-tryptophan (G34W) substitutions in H3.3 arise in
          approximately 90% of giant cell tumor of bone (GCT). Here, we show
          H3.3 G34W is necessary for tumor formation.
        explanation: >-
          States the necessity result this readout records.
    evidence:
    - reference: PMID:32967858
      reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Our findings suggest that H3.3 G34W leads to GCT by sustaining a
        transformed state in osteoblast-like progenitors, which promotes
        neoplastic growth, pathologic recruitment of giant osteoclasts, and bone
        destruction.
      explanation: >-
        The authors' summary of what perturbing the allele in this system
        establishes about the driver node.

- name: Monocyte osteoclastogenesis co-culture with GCTB stromal cells
  description: >-
    Peripheral monocytes cultured with GCTB stromal cells or their secreted
    factors, reading out multinucleated osteoclast formation. This is the
    system in which the paracrine arm of the disease is actually measured -
    including the recombinant-SCUBE3 add-back that tests the de-repression
    mechanism directly - and it is the one place the two compartments are
    reconstituted together.
  experimental_model_type: CO_CULTURE
  cell_source: Human peripheral blood monocytes with GCTB stromal cells
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:36138226
  evidence:
  - reference: PMID:36138226
    reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      While these striking features imply a pathogenic interaction between
      mesenchymal and myelomonocytic lineages during GCT development, the
      underlying mechanisms remain unknown.
    explanation: >-
      States the two-compartment interaction this co-culture system exists to
      reconstitute and measure.
  modeled_mechanisms:
  - target: Enhancer-Level SCUBE3 Repression
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      Quantifies osteoclast formation as a function of stromal SCUBE3, the
      readout that establishes SCUBE3 as a restraint rather than a bystander.
    limitations: >-
      An in vitro reconstitution of two purified compartments cannot reproduce
      the bone matrix, vasculature, or the recruitment step that precedes fusion
      in vivo; osteoclast number and size in a dish are a proxy for tumor
      osteolysis, not a measurement of it.
    readouts:
    - name: Osteoclast number and size generated from monocyte precursors
      target: Enhancer-Level SCUBE3 Repression
      direction: INCREASED
      interpretation: >-
        Osteoclast output rises as stromal SCUBE3 falls, the direction the
        de-repression model predicts.
      evidence:
      - reference: PMID:36138226
        reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          We show that the changes in the transcriptome and epigenome in the
          mesenchymal cells caused by the H3.3-G34W mutation contribute to
          increase osteoclast recruitment in part via reduced expression of the
          TGFβ-like soluble factor, SCUBE3.
        explanation: >-
          Reports the measured increase in osteoclast recruitment attributable
          to reduced SCUBE3.
    evidence:
    - reference: PMID:34556636
      reference_title: Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Stromal-derived SRGN promotes osteoclast differentiation from monocytes."
      explanation: >-
        An independent use of the same co-culture readout, supporting it as the
        established assay for the stromal-to-osteoclast axis.

animal_models:
- name: Naturally occurring canine vertebral giant cell tumor of bone
  description: >-
    A spontaneous primary lumbar extradural giant cell tumor in a 10-year-old
    Poodle, characterized by imaging, necropsy, histology, histochemistry, and
    immunohistochemistry. It reproduces the human tumor's cellular architecture
    - TRAP-positive osteoclastic giant cells evenly distributed among
    alpha-SMA-positive spindled mononuclear cells and IBA-1-positive histiocytic
    cells - and its destructive osteolysis. It is the only naturally occurring
    non-human example identified in this curation pass, and it is included for
    what it fails to show as much as for what it shows.
  species: Dog
  genotype: Not determined; spontaneous tumor in a wild-type animal
  publication: PMID:41908959
  evidence:
  - reference: PMID:41908959
    reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The final diagnosis was a primary lumbar extradural giant cell tumor of
      bone.
    explanation: >-
      Confirms the diagnosis in the animal, the basis for treating this
      spontaneous case as informative about the human disease.
  modeled_mechanisms:
  - target: Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The canine tumor contains the same tripartite cellular composition as the
      human disease, with abundant osteoclast-type multinucleated giant cells
      distributed among mononuclear stromal and histiocytic populations.
    limitations: >-
      A single spontaneous case, characterized only at necropsy. Fidelity is
      capped at MODERATE rather than HIGH because the compositional match is
      morphological and immunophenotypic; no genotyping was performed, so the
      canine giant cells are not shown to be reactive to a mutant stromal
      population in the way that defines the human mechanism.
    readouts:
    - name: TRAP-positive multinucleated giant cells distributed among mononuclear cells
      target: Recruitment and Fusion of Reactive Osteoclast-Like Giant Cells
      direction: INCREASED
      interpretation: >-
        Histochemical confirmation of an osteoclast-type giant cell population
        in the canine tumor.
      evidence:
      - reference: PMID:41908959
        reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          The tumor comprised numerous multinucleated giant cells of the
          osteoclastic type (positive for tartrate-resistant acid
          phosphatase- TRAP- and lysozyme), evenly distributed among
          mononuclear cells (both rounded and spindle-shaped).
        explanation: >-
          Reports the TRAP-positive giant cell population and its even
          distribution among mononuclear cells.
    evidence:
    - reference: PMID:41908959
      reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Alpha smooth muscle actin (SMA) was expressed in mononuclear cells,
        while IBA-1 staining highlighted mononuclear histiocytic cells.
      explanation: >-
        Documents the two mononuclear populations alongside the giant cells,
        establishing the compositional match that makes this animal informative
        for the node.
  - target: Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      Immunohistochemistry with the H3.3 G34W mutation-specific antibody showed
      no nuclear reactivity in the canine tumor. The animal reproduces the
      disease's cellular architecture without demonstrating the molecular driver
      that defines it in humans, so it cannot serve as a model of the
      oncohistone mechanism curated at this node.
    limitations: >-
      The negative result is not decisive about canine biology. The antibody is
      validated for human tissue only, so a species difference in the H3.3
      sequence context or simple loss of cross-reactivity would produce the same
      absent stain as a genuinely different driver. No sequencing was performed,
      and this is a single case. The honest reading is that the driver is
      undetermined in the dog, not that it is absent - which is precisely why
      the link is FAILS_TO_RECAPITULATE at LOW fidelity rather than a
      species-divergence claim.
    evidence:
    - reference: PMID:41908959
      reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Both masses exhibited whitish areas interspersed with blood-filled
        spaces.
      explanation: >-
        Establishes from the abstract that this is the canine tumor in question.
        Recorded as PARTIAL because the abstract does not itself report the
        G34W immunohistochemistry; that result appears in the report body, and
        the failure-to-recapitulate claim rests on it rather than on this quote.
  notes: >-
    The G34W-negative immunohistochemistry is stated in the case report's
    results and discussion rather than its abstract, so it is not quoted as a
    snippet here - abstract-only reference validation would not verify it. The
    open question it raises is curated as a HUMAN_MODEL_MISMATCH discussion.

discussions:
- discussion_id: gctb_no_in_vivo_g34w_model
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells"
  - "pathophysiology#Enhancer-Level SCUBE3 Repression"
  prompt: >-
    Does the H3.3-G34W oncohistone initiate a giant cell tumor in vivo, and does
    the stromal-to-osteoclast paracrine loop operate as modeled when both
    compartments are present in a living skeleton?
  rationale: >-
    Every mechanistic step curated in this entry between the mutation and the
    osteoclast compartment - the epigenetic reprogramming, the differentiation
    block, SCUBE3 de-repression, the SEMA4D return signal - rests on
    patient-derived cultures, edited tumor-derived cell lines, and monocyte
    co-cultures. No genetically engineered animal carrying a knock-in G34W
    allele was identified in this curation pass. That matters more here than in
    most diseases, because the central claim is specifically about cross-talk
    between two cell compartments: a monoculture cannot test it, and a
    co-culture reconstitutes it only in the absence of bone matrix, vasculature,
    and an intact recruitment step. The tumor-formation experiment that
    establishes necessity was performed in cells that were already
    tumor-derived, so initiation from a normal mesenchymal progenitor remains
    untested.
  proposed_experiments:
  - experiment_id: gctb_conditional_g34w_knockin
    name: Conditional H3-3A G34W knock-in in the osteoblast lineage
    description: >-
      Generate a conditional knock-in of the G34W allele driven in mesenchymal
      or osteoprogenitor lineages and determine whether a giant-cell-rich
      osteolytic lesion arises, whether the recruited osteoclasts are
      genotypically wild type, and whether Scube3 is repressed in the mutant
      stroma in situ.
    readouts:
    - name: Formation of a giant-cell-rich osteolytic lesion
      target: Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells
      direction: INCREASED
      interpretation: >-
        Lesion formation from a normal progenitor would establish sufficiency,
        which the existing edited-cell experiment cannot.
      evidence:
      - reference: PMID:32967858
        reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Here, we show H3.3 G34W is necessary for tumor formation."
        explanation: >-
          The existing necessity result this proposed readout would extend to
          sufficiency in vivo.
    - name: Scube3 expression in mutant stroma in situ
      target: Enhancer-Level SCUBE3 Repression
      direction: DECREASED
      interpretation: >-
        In vivo confirmation that the de-repression step operates outside
        culture.
      evidence:
      - reference: PMID:36138226
        reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Transcriptional changes in SCUBE3 are associated with altered histone
          marks and H3.3G34W enrichment at its enhancer regions.
        explanation: >-
          The in vitro finding this readout is designed to test in a living
          skeleton.
    evidence:
    - reference: PMID:36138226
      reference_title: Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        While these striking features imply a pathogenic interaction between
        mesenchymal and myelomonocytic lineages during GCT development, the
        underlying mechanisms remain unknown.
      explanation: >-
        States the two-compartment interaction that only an in vivo model can
        test intact, motivating this experiment.
  evidence:
  - reference: PMID:32967858
    reference_title: H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      By profiling the epigenome, transcriptome, and secreted proteome of
      patient samples and tumor-derived cells CRISPR-Cas9-edited for H3.3 G34W
    explanation: >-
      Documents that the necessity evidence comes from edited tumor-derived
      cells, the limitation this gap identifies.

- discussion_id: gctb_canine_driver_mismatch
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - "pathophysiology#Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells"
  prompt: >-
    Is the only naturally occurring animal counterpart of this disease driven by
    the same oncohistone, or does the canine tumor reach the same histology by a
    different molecular route?
  rationale: >-
    The canine vertebral case reproduces the human tumor's architecture -
    osteoclastic giant cells evenly distributed among spindled mononuclear cells
    - and its destructive osteolysis, yet showed no nuclear reactivity with the
    H3.3 G34W mutation-specific antibody. Three readings are compatible with
    that result and they have different consequences. If the antibody, validated
    only in human tissue, simply fails to cross-react, the dog is a usable model
    of the human mechanism. If canine H3.3 differs in sequence context around
    codon 34, the species is uninformative about this driver. If canine giant
    cell tumors are genuinely driven by something else, then the shared
    histology is convergent, and the tumor's architecture is a general outcome
    of stromal-osteoclast cross-talk rather than a specific consequence of this
    oncohistone - which would be the most interesting result of the three, and
    would argue that the histology is not diagnostic of the mechanism. Nothing
    short of sequencing distinguishes them.
  proposed_experiments:
  - experiment_id: gctb_canine_h3f3a_sequencing
    name: Targeted sequencing of H3-3A codon 34 in canine giant cell tumors
    description: >-
      Sequence the H3-3A codon 34 region in a series of canine giant cell bone
      tumors, alongside alignment of the canine H3.3 epitope against the human
      sequence the antibody was raised to, to separate assay failure from true
      molecular divergence.
    readouts:
    - name: Presence of a codon 34 substitution in canine tumor stromal cells
      target: Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells
      direction: UNCHANGED
      interpretation: >-
        Absence of any codon 34 change with a conserved epitope would establish
        genuine divergence; presence with a negative stain would establish assay
        failure. Direction is recorded as UNCHANGED because the informative
        result is the wild-type one.
      evidence:
      - reference: PMID:33021329
        reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Furthermore, one case of GCTB and one case of recurrent GCTB showed
          positive G34W immunostaining results despite being negative for the
          genetic mutation.
        explanation: >-
          Demonstrates in human tissue that stain and sequence can disagree,
          which is why sequencing rather than immunohistochemistry is the
          discriminating readout proposed here.
    evidence:
    - reference: PMID:41908959
      reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The final diagnosis was a primary lumbar extradural giant cell tumor of
        bone.
      explanation: >-
        Establishes the canine case that would supply the material for this
        experiment. PARTIAL because the abstract does not report the
        immunohistochemistry that motivates it.
  evidence:
  - reference: PMID:41908959
    reference_title: 'Case Report: Histochemical and immunohistochemical characterization of a canine giant cell bone tumor in lumbar spine.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The final diagnosis was a primary lumbar extradural giant cell tumor of
      bone.
    explanation: >-
      Establishes the diagnosis in the animal. PARTIAL because the abstract does
      not report the G34W immunohistochemistry on which the mismatch rests; that
      appears in the report body.

- discussion_id: gctb_denosumab_recurrence_after_withdrawal
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - "pathophysiology#Stromal RANKL Overexpression"
  - "pathophysiology#Local Recurrence After Incomplete Removal"
  prompt: >-
    Does neoadjuvant denosumab increase the risk of local recurrence after
    subsequent curettage, and if so, is that an artefact of indication bias or a
    real consequence of leaving mutant stroma in a drug-induced quiescent state?
  rationale: >-
    The mechanism predicts the problem. Denosumab acts on RANKL, depleting the
    reactive osteoclast compartment; in cell-line work it neither inhibits the
    growth of nor kills the neoplastic stromal cells, and it does not alter
    their RANKL or OPG expression. The compartment that carries the driver
    mutation is therefore untouched, and the new bone the drug induces may make
    residual tumor harder to identify and clear at surgery. Reported recurrence
    after denosumab-then-surgery ranges from 20% to 100% across a systematic
    review - a spread wide enough to be uninformative on its own, and one that
    could equally reflect indication bias, since the drug is given to the worst
    tumors. Resolving this needs a design that controls for baseline tumor
    severity, which no published study has.
  evidence:
  - reference: PMID:24060052
    reference_title: Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In contrast, denosumab only exerted a minimal inhibitory effect in one
      cell line and did not induce any apoptosis.
    explanation: >-
      Establishes that the drug does not kill the neoplastic stromal cells, the
      mechanistic basis of the recurrence concern.
  - reference: PMID:24060052
    reference_title: Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Our findings provide new insights in the anti-tumor effect of denosumab on
      GCT stromal cells and raise a concern that tumor recurrence may occur
      after the withdrawal of the drug.
    explanation: >-
      The authors state the withdrawal-recurrence concern that this discussion
      records.
  - reference: PMID:32541321
    reference_title: Current concepts in the treatment of giant cell tumour of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Concerns have arisen that recurrence rates would be higher than after
      conventional treatment, ranging from 20 to 100% in a systematic review,
      although this may be because of bias.
    explanation: >-
      Gives both the reported range and the bias caveat, which is why this is
      recorded as an open controversy rather than a settled effect. Evidence
      source is OTHER because this is a review article.
  - reference: PMID:35837707
    reference_title: Updated concepts in treatment of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Increased experience with use of denosumab raised concern on elevated
      recurrence rates. However, conclusions of meta-analyses should be
      interpreted with risk of indication bias in mind.
    explanation: >-
      An independent review reaching the same unresolved position, naming
      indication bias explicitly. Evidence source is OTHER because this is a
      review article.

- discussion_id: gctb_paget_associated_familial_subset
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells"
  prompt: >-
    What inherited factor predisposes to giant cell tumor arising in Paget
    disease of bone, and does that subset share the H3-3A G34W driver curated
    for conventional sporadic GCTB?
  rationale: >-
    This entry models conventional sporadic GCTB and asserts no inheritance. A
    distinct subset contradicts that framing at the level of the disease name,
    and is recorded here rather than silently dropped. Giant cell tumor arising
    in Paget disease clusters strongly in families, is disproportionately
    multifocal, favours flat bones over the long-bone epiphyses this entry
    describes, and carries roughly 50 percent five-year mortality against 0 to 5
    percent for GCT without Paget disease. The predisposition is most plausibly
    inherited through Paget disease genetics rather than through anything in the
    mechanism graph curated here, but the retrieved literature does not
    establish the germline basis of the GCT phenotype specifically, and does not
    report whether these tumors carry H3-3A G34W at all. Until that is known it
    is not possible to say whether PDB-associated GCT is the same disease
    arising on a permissive background, or a mechanistically separate entity
    sharing a histological name - which is why it is scoped out of this entry
    rather than merged into it, and why a separate entry would be the right
    home for it.
  proposed_experiments:
  - experiment_id: gctb_pdb_associated_driver_and_germline
    name: H3-3A genotyping and germline sequencing of PDB-associated giant cell tumors
    description: >-
      Genotype H3-3A codon 34 in a series of PDB-associated giant cell tumors
      and sequence germline DNA from affected kindreds, to determine whether the
      subset shares the sporadic driver and whether a segregating predisposition
      allele accounts for the familial clustering.
    readouts:
    - name: H3-3A codon 34 mutation status in PDB-associated giant cell tumors
      target: Somatic H3-3A G34W Oncohistone Mutation in Mesenchymal Stromal Cells
      direction: UNCHANGED
      interpretation: >-
        Wild-type codon 34 would establish PDB-associated GCT as a
        mechanistically distinct entity; G34W would place it on the same
        pathograph with an inherited permissive background. Direction is
        recorded as UNCHANGED because the entity-separating result is the
        wild-type one.
      evidence:
      - reference: PMID:33021329
        reference_title: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Sanger DNA sequencing analysis was used to detect H3F3A mutations.
        explanation: >-
          The established assay this readout would apply to the PDB-associated
          subset.
  evidence:
  - reference: PMID:25196811
    reference_title: "Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with Paget's bone disease (PDB) have an increased risk of
      developing giant cell tumor (GCT).
    explanation: >-
      Establishes the existence of the subset this discussion scopes out.
  - reference: PMID:25196811
    reference_title: "Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mortality rate of PDB-GCT patients was higher than those occurring in
      GCT patients without PDB (about 50% versus 0% to 5% at 5 years)
    explanation: >-
      Quantifies the prognostic gulf between the subset and conventional GCTB,
      the strongest argument that the two should not be modeled as one entry.
  - reference: PMID:25196811
    reference_title: "Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      one-fourth of them (24.8%) had multifocal GCTs
    explanation: >-
      Documents the multifocality that distinguishes the subset from the
      typically monostotic sporadic disease.

stages:
- name: Campanacci Grade I (latent)
  description: >-
    A well-marginated intraosseous lesion with an intact cortex. Managed with
    extended intralesional curettage plus adjuvant; recurrence risk is lowest in
    this group.
  role: early
- name: Campanacci Grade II (active)
  description: >-
    A relatively well-defined lesion without a radiopaque rim, with cortical
    thinning and moderate expansion. Still the domain of joint-preserving
    intralesional surgery.
  role: intermediate
- name: Campanacci Grade III (aggressive)
  description: >-
    Ill-defined margins, cortical destruction, and soft-tissue extension. Grade
    III is the point at which the curettage-versus-resection calculation flips:
    intralesional treatment carries a markedly higher recurrence risk here, and
    grade III is independently a risk factor for pulmonary implantation. It is
    also the setting where neoadjuvant denosumab is used to downstage before
    surgery.
  role: advanced
  evidence:
  - reference: PMID:22773395
    reference_title: 'Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intralesional excision appears to be more appropriate for the treatment of
      local lesions (e.g., grades 1 and 2) than grade 3 GCTs of the distal
      radius
    explanation: >-
      Establishes grade III as the threshold at which intralesional treatment
      becomes the less appropriate option.
  - reference: PMID:28443231
    reference_title: Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Campanacci stage of all tumors was stage 3."
    explanation: >-
      Every tumor in a 46-patient lung-metastasis series was Campanacci stage 3,
      supporting the association between this stage and pulmonary implantation.
  - reference: PMID:20934816
    reference_title: Features of grade 3 giant cell tumors of the distal radius associated with successful intralesional treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with a single site of cortical perforation who received CCC
      treatment achieved local control with intralesional treatment alone.
    explanation: >-
      Qualifies the grade III rule: a subset with limited cortical perforation
      can still be managed intralesionally, so the grade is a guide rather than
      a hard boundary. Recorded as PARTIAL for that reason.
  notes: >-
    Campanacci grading is radiographic-surgical rather than an oncological
    stage; it describes local aggressiveness, not the benign/malignant
    distinction, which is captured separately by the Malignant Sarcomatous
    Transformation node.

diagnosis:
- name: Radiographic signature of giant cell tumor of bone
  description: >-
    The lesion is diagnosed largely on its radiographic pattern in a specific
    clinical context: a purely lytic, geographically destructive lesion with
    circumscribed non-sclerotic borders, centred in the epiphysis but reaching
    the metaphysis and extending to the adjacent articular cortex, with no
    mineralized tumor matrix, in a patient with closed physes. Skeletal maturity
    is doing real diagnostic work here - it is the main clinical discriminator
    from chondroblastoma, which is also epiphyseal but occurs before physeal
    closure.
  evidence:
  - reference: PMID:21139758
    reference_title: Imaging of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      On radiographs, GCT demonstrates a lytic lesion centered in the epiphysis
      but involving the metaphysis and extending at least in part to the
      adjacent articular cortex.
    explanation: >-
      States the defining radiographic location and extent. Evidence source is
      OTHER because this is a review article.
  - reference: PMID:21139758
    reference_title: Imaging of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Most cases show circumscribed borders or so-called geographical
      destruction with no periosteal reaction unless a pathological fracture is
      present. There is no mineralized tumor matrix.
    explanation: >-
      Gives the margin and matrix characteristics that separate this lesion from
      matrix-forming and permeative bone tumors. Evidence source is OTHER
      because this is a review article.
  - reference: PMID:21139758
    reference_title: Imaging of giant cell tumor of bone.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Giant cell tumor (GCT) of bone is a benign but locally aggressive and
      destructive lesion generally occurring in skeletally mature individuals.
    explanation: >-
      Establishes skeletal maturity as part of the diagnostic context. Evidence
      source is OTHER because this is a review article.
  notes: >-
    Imaging narrows the differential but does not close it. The definitive
    discriminator against giant-cell-rich mimics is H3.3 G34W mutant-protein
    immunohistochemistry or H3-3A sequencing, curated under histopathology.

references:
- reference: PMID:24162739
  title: >-
    Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant
    cell tumor of bone.
- reference: PMID:32967858
  title: >-
    H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like
    Mesenchymal Progenitors in Giant Cell Tumor of Bone.
- reference: PMID:33110075
  title: >-
    Globally altered epigenetic landscape and delayed osteogenic differentiation
    in H3.3-G34W-mutant giant cell tumor of bone.
- reference: PMID:36138226
  title: >-
    Aberrant paracrine signalling for bone remodelling underlies the mutant
    histone-driven giant cell tumour of bone.
- reference: PMID:33021329
  title: >-
    H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in
    366 cases of giant cell tumors of bone and other bone tumors.
- reference: PMID:22662295
  title: >-
    Modern interpretation of giant cell tumor of bone: predominantly
    osteoclastogenic stromal tumor.
- reference: PMID:29944971
  title: "Giant cell tumor of bone: updated molecular pathogenesis and tumor biology."
- reference: PMID:34556636
  title: >-
    Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell
    tumor of bone.
- reference: PMID:20149736
  title: >-
    Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2
    study.
- reference: PMID:31704134
  title: >-
    Denosumab in patients with giant-cell tumour of bone: a multicentre,
    open-label, phase 2 study.
- reference: PMID:26033180
  title: >-
    Surgical downstaging in an open-label phase II trial of denosumab in
    patients with giant cell tumor of bone.
- reference: PMID:24060052
  title: >-
    Comparison of the anti-tumor effects of denosumab and zoledronic acid on the
    neoplastic stromal cells of giant cell tumor of bone.
- reference: PMID:32541321
  title: "Current concepts in the treatment of giant cell tumour of bone."
- reference: PMID:35837707
  title: "Updated concepts in treatment of giant cell tumor of bone."
- reference: PMID:39236154
  title: >-
    The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell
    Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of
    Recurrence in 1,454 Patients.
- reference: PMID:22773395
  title: "Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis."
- reference: PMID:21301899
  title: >-
    The prognostic factors of recurrent GCT: a cooperative study by the Eastern
    Asian Musculoskeletal Oncology Group.
- reference: PMID:28443231
  title: >-
    Clinical characteristics and risk factors analysis of lung metastasis of
    benign giant cell tumor of bone.
- reference: PMID:34785767
  title: >-
    Histological and immunohistochemical features and genetic alterations in the
    malignant progression of giant cell tumor of bone: a possible association
    with TP53 mutation and loss of H3K27 trimethylation.
- reference: PMID:31285528
  title: "Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone."
- reference: PMID:29987945
  title: >-
    Incidence and demographics of giant cell tumor of bone in The Netherlands:
    First nationwide Pathology Registry Study.
- reference: PMID:21139931
  title: >-
    The epidemiology of malignant giant cell tumors of bone: an analysis of data
    from the Surveillance, Epidemiology and End Results Program (1975-2004).
- reference: PMID:23378375
  title: "Giant cell tumor of bone."
- reference: PMID:28905737
  title: "Giant cell tumor of bone revisited."
- reference: PMID:36502615
  title: >-
    Best clinical management of tenosynovial giant cell tumour (TGCT): A
    consensus paper from the community of experts.
- reference: PMID:23708046
  title: >-
    Giant cell tumor with secondary aneurysmal bone cyst: a unique presentation
    with an ossified extraosseous soft tissue mass.
- reference: PMID:21139758
  title: Imaging of giant cell tumor of bone.
- reference: PMID:21045974
  title: >-
    Giant cell tumor of the sacrum and spine: series of 23 cases and a review of
    the literature.
- reference: PMID:29745092
  title: >-
    Therapeutic benefits of neoadjuvant and post-operative denosumab on sacral
    giant cell tumor: a retrospective cohort study of 30 cases.
- reference: PMID:20934816
  title: >-
    Features of grade 3 giant cell tumors of the distal radius associated with
    successful intralesional treatment.
- reference: PMID:25196811
  title: "Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone."
- reference: PMID:41908959
  title: >-
    Case Report: Histochemical and immunohistochemical characterization of a
    canine giant cell bone tumor in lumbar spine.

📚